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ABSTRACT 
With an estimated 5 million people suffering from valve disease in the 
United, valve disease is currently the leading cause of cardiovascular disease.1  Each 
year, between 80,000 and 85,000 aortic valve replacements are performed in order 
to treat the stenotic heart valves. Despite this being a worldwide epidemic, the 
current valve replacement options that are on the market have distinct limitations.  
Furthermore, a viable alternative does not exist for the patients that are not 
candidates for the current treatment methods. Our proposed solution to this 
epidemic is to create a highly viable injectable scaffold that would allow for the 
minimally invasive delivery of human adipose-derived stem cells (hADSCs), as well 
as to provide necessary biological cues for growth and remodeling to the scaffold. 
A process was created to create a hydrogel derived from decellularized 
porcine aortic cusp tissue.  The aortic cusp was solubilized using an acid-pepsin 
solution, neutralized and reformed as a hydrogel structure.  This processing was 
analyzed for effectiveness of decellularization, retention of the extracellular matrix 
components, scaffold architecture, and cell interaction and viability. 
Histology showed proper decellularization while maintaining the 
components of the extracellular matrix throughout the fabrication process, collagen 
content analysis provided further evidence of this.  Quantitative analysis of H&E 
sections revealed a highly porous scaffold, conducive to cell migration.  Rheological 
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studies revealed shear thinning properties that is advantageous for the ability of the 
scaffold to be injected.  A Live/Dead assay of the scaffold showed an extremely 
viable scaffold in static conditions, as well as a tendency of the cells to contract and 
remodel the hydrogel. 
Present studies have optimized the technique for creation of the hydrogel, 
characterized the biological and physical properties of the scaffold, and determined 
the viability of the scaffold for seeding of hADSCs.  These aortic cusp-derived 
scaffolds provide an environment that mimics the aortic cusp ECM.  This research 
will advance cardiovascular tissue engineering and further aid in the search for the 
ideal tissue engineered heart valve. 
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CHAPTER 1: INTRODUCTION 
AND BACKGROUND 
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1.1 Structure and components of the cardiovascular system 
The cardiovascular system serves as a closed system that circulates blood 
throughout the body in order to deliver nutrients and oxygen to the body.  This 
system consists of two circuits, the pulmonary circuit and the systemic system.  The 
pulmonary circuit is responsible for oxygenating the blood and eliminating the 
carbon dioxide from the blood.  The systemic circuit is responsible for delivering the 
oxygenated blood and nutrients to the body, as well as to remove the waste from 
those cells.  These circuits work together to keep the cells from becoming deprived 
of the necessary nutrients to survive.  At the center of this system is the muscular 
pump in charge of pushing the blood throughout the system, known as the heart.  
The heart works through continuous contractions and relaxations, known as the 
cardiac cycle.  The heart is a very hard working organ that is responsible for 
pumping 7,000 liters of blood through the system, every single day.2 
1.1.1 Pericardium and the tissue layers of the wall 
The protection of the heart is charged to the pericardial sac, which covers the 
heart with three layers of pericardium: the fibrous pericardium, parietal 
pericardium, and the visceral pericardium.  The outermost layer of the pericardial 
sac, the fibrous pericardium, is responsible for providing a tough and protective 
layer of dense connective tissue.  This layer is attached to the diaphragm, the 
vertebral column, and the large blood vessels that emerge from the heart2.  The 
other two layers, the visceral and parietal pericardium, form a double layered 
serous membrane.  Between these two layers is a space called the pericardial cavity, 
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containing serous fluid.  This fluid is secreted by the membranes of the pericardial 
cavity in order to reduce the amount of friction between the pericardium and the 
heart.  The innermost layer, the visceral pericardium, corresponds to the 
epicardium, which is the outer layer to the wall of the heart.3 
The wall of heart is comprised of three different layers of tissue: the 
epicardium, myocardium, and endocardium.  The epicardium is the outermost layer 
of the wall, which is connected to the visceral pericardium.  This layer of tissue 
reduces the amount of friction that the heart is subjected to, which helps contribute 
to protecting of the heart.  This layer consists of connective tissue that includes 
capillaries for both blood and lymph, as well as nerve fibers.  The next layer of the 
wall is the myocardium, which is made up of cardiac muscle tissue that contracts to 
pump blood out of the chambers.  This layer consists both of the muscle fibers used 
to contract the chambers and the connective tissue that allows blood and lymph 
capillaries to run through the muscle fibers.  The innermost layer of the wall is the 
endocardium, which is comprised of connective tissue, epithelial tissue, blood 
vessels and Purkinje fibers.  This layer lines all the chambers and covers the heart 
valves and other structures of the heart.  The anatomy of the wall of the heart, as 
well as the pericardial sac, is pictured below in Figure 1.2 
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1.1.2 Valves and chambers of the heart 
There are four internal cavities that divide the heart into sections, known as 
chambers.  There are two chambers on the right and two chambers on the left, each 
of which lead to different parts of the cardiovascular system.  The upper chambers 
of the heart are known as the atria, which are thin walled and accept the blood that 
is returning to the heart through the cardiovascular system.  The lower chambers, 
are known as the ventricles, are responsible for forcing the blood inside the 
chambers of the heart back out into the arteries.  The right atrium is responsible for 
receiving blood from the superior and inferior vena cava, which returns blood from 
the body that is low in oxygen.  The left atrium is responsible for receiving 
oxygenated blood from the pulmonary veins, which returns the blood from the 
lungs.  The left ventricle is specifically responsible for receiving the blood from the 
left atrium and forcing the blood to all other parts of the body.  The right ventricle is 
Figure 1: The three layers of the wall of the heart and the three layers 
of the pericardial sac.2
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responsible for receiving the blood from the right atrium and pumping it out to the 
Due to the fact that the left ventricle has to push the blood a much greater distance 
than the right ventricle, the walls of the left ventricle are therefore much more 
muscular in order to be capable of moving the blood the required distance.  The 
layout of the chambers of the heart, as well as how they interact with the rest of the 
cardiovascular system, is shown in Figure 2 below.3 
Figure 2: Anatomy of the Chambers and Valves of the Heart3 
The chambers of the heart are divided by four valves, which function as 
gateways for the blood to be pumped through.  These valves allow the blood to 
move from one side to the other without backflow occurring.  Similar to there being 
two types of chambers, there are also two types of valves.  One of the types of valve 
is called the atrioventricular valve and as its name suggests, these two valves 
separate their respective atria and ventricle.  These valves open when the blood 
pressure is greater on the side of the atria and the valve will close when the blood 
pressure is greater on the side of the ventricle. The tricuspid valve covers the large 
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orifice between the right atria and right ventricle with its three leaflets structure 
and the mitral valve covers the large orifice between the left atrium and left 
ventricle with its bi-leaflet structure.  These valves also have chordae tendineae, or 
fibrous tissue strings, that prevent the valves from swinging backwards into the 
atrium.  The second type of valves are the semilunar valves, the name of which 
comes from the half-moon shape of the cusps of the valve.  The two valves that make 
up this category are the pulmonary valve, which covers the entrance to the 
pulmonary trunk, and the aortic valve, which covers the entrance to the aorta.  
These valves open upon contraction of the ventricular wall to allow blood to rush 
out of the heart and into the rest of the system.  These valves close upon the 
relaxation of the ventricular wall to prevent backflow into the ventricles.  The 
anatomy of these four valves are shown in Figure 3 below.2 
Figure 3: Superior view of the heart depicting all four heart valves.2 
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1.1.3  Blood vessels and blood flow 
To understand the need for the complexity of the cardiovascular system, the 
route, purpose, and interactions of the blood with the rest of the body must be fully 
understood.  Deoxygenated blood travels enters the heart, leaving the venae cava 
and coronary sinus and enters the right atrium.  The blood then passes through the 
tricuspid valve into the right ventricle, which then enters the pulmonary circuit 
upon contraction of the right ventricle and opening of the pulmonary valve.  The 
blood travels to lungs through the pulmonary arteries in which the oxygen exchange 
occurs in the capillaries of the alveoli.  Once the gas exchange occurs, the oxygenated 
blood returns to the heart through the pulmonary veins, enters the left atrium, then 
passes into the left ventricle through the mitral valve.  The blood is then pushed 
through the aortic valve upon ventricular contraction and into the systemic circuit.  
This circuit is responsible for delivering the nutrients and gas that the newly 
oxygenated blood into the tissue cells through the thinly walled capillaries.  The 
deoxygenated blood then returns through the systemic veins and into right atrium, 
completing the entire circuit.  The entirety of this process can be seen in Figure 4.2 
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Figure 4: Diagram of the path blood takes throughout the body, picturing the both the pulmonary and 
systemic circuit.2 
Due to the blood traveling through the systemic circuit having a much larger 
distance to travel, the aortic and mitral valves is subjected to a larger amount of 
shear stress than the pulmonary and tricuspid valves.  This increase in shear stress 
contributes to the higher incidence of disease in the aortic and mitral valves. 
1.2 Anatomy and physiology of the aortic valve 
In order to design an effective replacement for a diseased aortic valve, the 
entirety of the aortic valvar complex should be completely understood4.  This 
complex consists of all the components of the aortic root and the ascending aorta.  
The aortic root is the lower part of the aortic valvar complex that contains the 
leaflets of the valve, the sinotubular junction, the annulus, the inter-leaflet triangles, 
and the Sinus of Valsalva.  The anatomy of the aortic valvar complex is shown below 
in Figure 5. 
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Figure 5: Diagram of the path blood takes throughout the body, picturing the both the pulmonary and 
systemic circuit.5 
The normal aortic valve has a tri-leaflet structure and the interaction 
between these leaflets is responsible for whether or not the valve is functioning 
properly.  These leaflets work together to form a boundary between the ascending 
aorta and the left ventricle and acts as a hemodynamic junction.  This tri-leaflet 
design is optimized for a low resistance opening and high level of efficiency in the 
cardiovascular system.5  This tri-leaflet structure is very important to the 
functionality of the valve, which can be seen with the pathology of the bicuspid 
defect in those with congenital defects.  Recreating the functionality of the tri-leaflet 
stricture when trying to create a working valve replacement is imperative creating a 
permanent solution to a diseased valve. 
Every one of these components works in harmony in order to create a 
functioning complex that pumps oxygenated blood throughout the body.  When an 
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aortic valve becomes diseased it can be a result of the valve not functioning 
properly, but can also be caused by dysfunction in the other parts of the complex.  
1.2.1 Tissue layers of the aortic valve 
While the structure of the aortic root complex, the structure of the leaflets of 
the aortic valve are also extremely important to the functionality of the valve.  The 
importance of the structure is at both a macro- and a micro-level, as seen in Figure 
6. The three layers are known as the fibrosa, spongiosa, and ventricularis.
Figure 6:Cross section of an aortic cusp, showing the three layers: fibrosa, spongiosa, and ventricularis.6 
These layers contain different components that ultimately decide the 
properties of the valve.7  The ventricularis is the layer located on the left ventricular 
side of the valve.  This layer of the valve is made up of a layer of elastin fibers with 
are arranged radially to reduce the strain caused by the inflow of blood.  The middle 
layer, known as the spongiosa, is made up of glycosaminoglycans (GAGs).  These 
GAGs are long, unbranched polysaccharides which help to lubricate the ventricularis 
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and fibrosa layers, helping to cut down on the shear and deformation that the 
cardiac cycle causes.  The layer on the aorta side of the valve is called the fibrosa.  
This layer is made of two types of fibrillar collagen (Type I and Type III), which 
serves as the load-bearing layer of the leaflet.  This is done with a circumferential 
formation of these collagen fibers.  Each of the layers also has layers of valve 
endothelial cells (VECs) lining the outside of the leaflets and valve in valve 
interstitial cells (VICs).  The endothelial lining of the leaflets help to maintain 
homeostasis of the valves.  This is done through a variety of mechanisms including 
regulating permeability, paracrine signaling, and inflammatory cell adhesion7.  The 
valve interstitial cells of each layer serve as the source of components for the 
extracellular matrix of the tissue.  These components consist of collagen, elastin, and 
GAGs and they provide the necessary strength and elasticity for a functioning leaflet, 
as seen in Figure 7.   
Figure 7: Three layers of the aortic valve: the fibrosa, spongiosa, and ventricularis.  Each layer is lined 
with valve interstitial cells.7 
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1.2.2 Importance of the Valve Interstial Cells and Valve Endothelial Cells 
As discussed in the previous section, VICs and VECs both play an enormous 
role in the biological function of the aortic valve.  The interstitial cells are of 
particular interest because they are the most common cell present in the valve.8  
This cell type a mesenchymal cell type and therefore can be differentiated into the 
different phenotypes of VICs from the embryonic mesenchymal cell type.  The five 
different phenotypes of VICs are the embryonic progenitor mesenchymal stem cells, 
quiescent VICs, activated VICs, progenitor VICs and osteoblastic VICs.  Each of these 
different phenotypes serve a different function and all of them can be found in the 
leaflet of the heart valve.  Because of the diversity of the functions of the different 
phenotypes, it is important that when trying to utilize these cells in tissue 
engineered aortic valves, the correct phenotype is used in order to utilize the 
correct function and give the most functional valve.  The quiescent VICs are 
responsible for maintaining the valve’s structure and function, as well as to inhibit 
angiogenesis in the valve.  The activated VICs function as the repairmen of the valve, 
working to repair and remodel diseased valves.  These cells respond to the 
abnormal hemodynamic or mechanical conditions consistent with pathological 
valves and work to remodel the extracellular matrix of the leaflet.  The progenitor 
VICs are a recently discovered phenotype of VICs, thought to be derived from 
hematopoietic cells during a time of injury, meaning they also respond to the 
degenerated and diseased tissue and help to remodel the cells.  This pathway of 
differentiation from a separate cell line is particularly interesting, as these cells have 
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a similar function to that of the activated VICs, but only arise in the presence of 
pathogenic valves and have different markers than the activated VICs.  The last 
phenotype of adult VICs is osteoblastic VICs.  This last phenotype is differentiated 
from the quiescent VICs, but unlike those cells, the osteoblastic has a role in 
calcification of the heart valve and the degradation of the ECM.  This particular 
phenotype gets its name from its function, which is very similar to that of the 
osteoblasts that remodel the bone matrix.  This cell is undesirable in the leaflets 
because it can lead to a stenotic valve through the calcification of both a native valve 
and a tissue engineered valve, so steps must be taken to inhibit this differentiation 
process in a TEV.  A number of methods to inhibit the calcification of the osteoblastic 
VICs such as the addition of an anti-apoptic agent ZVAD-FMK or the use of matrix 
metalloproteinases (MMPs) to regulate calcification and ECM degradation in the 
leaflets, but ultimately very little is known about the inhibition of these osteoblastic 
VICs.  More research should be done with this phenotype in order to be able to 
effectively inhibit the differentiation and function that leads to stenotic heart valves. 
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Figure 8: An organizational chart of the phenotypes of VICs, depicting both the differentiation pathway 
and the function of each phenotype.8 
1.3 Pathology of the aortic valve 
1.3.1 Prevalence of aortic valve disease 
Cardiovascular disease (CVD) is one of the most common causes of death in 
the world, killing 678,000 people in 2010 in the United States alone, 1.68 million 
worldwide.9  The most frequent subtype of CVD is an aortic valve disease (AVD), 
which can be diagnosed by a few different characteristics.  One of the more common 
type of AVD is a congenital defect, or one that is developed at birth, known as the 
bicuspid aortic valve (BAV).  BAV is a defect in which the affected party effectively 
only has two leaflets of the aortic valve, either by partial or total fusion of two 
leaflets.  This defect is estimated to be present in three million people across the 
world and is also estimated to occur in 1.3% of new born infants.10  Because this 
defect of the aortic valve is congenital, the incidence is not affected by age, as it is 
acquired at birth. In addition to a congenital defect of the aortic valve, AVD also can 
15 
include aortic valve stenosis, which is present in about 54,000 people in the United 
States.  This disease is found more frequently in older patients, as it is usually a 
result of calcium build up on the leaflets of the valve over time. 
1.3.2 Pathology of common aortic valve diseases 
There are many risk factors associated with the development of a valve 
disease, many of which are also associated with the myriad of cardiac diseases that 
can lead to cardiac events such as infarctions and cardiac failure.  Advanced 
hypertensive, diabetic individuals, or individuals that have been exposed to certain 
infections, such as the bacteria associated with rheumatic fever, are some factors 
that put individuals at a higher risk for developing a heart valve disease11. Once the 
valve begins to function abnormally, it is characterized by an irregular heartbeat, or 
a murmur, and can usually be heard before any other symptoms occur in patients.  
This murmur of the heart is usually a sign that the valve is becoming stenotic, or is 
unable to open fully and properly, obstructing blood flow12. 
In the pathogenesis of these diseased heart valves, there are a few pathways 
that the valve can take to reach a state of dysfunction. An advanced bacterial 
infection caused by either the staphylococcus bacteria or syphilis could cause an 
inflammation and thickening of the valve, but only in the event that the valve had 
already been previously inflamed by another event, such as a myocardial infarction 
(MI).13  The valve undergoes a thrombotic effect through the collagen of the valve 
attracting platelets to the surface, resulting in thrombus formation, and the 
resultant endothelial damage to the valve can be permanent.  This condition is called 
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infective endocarditis, though the advent of penicillin and the decline of rheumatic 
fever have rendered this pathway of disease a thing of the past in the modern world.  
1.3.3 Calcification of the aortic valve 
Another pathway of valvular degeneration is by way of the calcification of the 
heart valves, which is limited to the left side of the heart’s valves, the aortic and the 
mitral valves.  This calcification is one of the main causes for stenosis of the valves, 
due to the calcium deposits causing a narrowing and stiffness of the valve13.  This 
degenerative calcification develops in the cusp fibrosa tissue and results in calcific 
aortic valve disease (CAVD).  The calcium deposits on the surface of the cusps of the 
valve, which forms masses of calcium build up and stiffens and thickens the valve.  
The valve will eventually accumulate enough calcium on the surface that it loses its 
mobility, becoming stenotic, as seen in Figure 9. 
Figure 9: A comparison of a healthy aortic heart valve and a stenotic valve caused by calcification.14 
The calcium deposits can also become so large that they project into the 
aortic sinuses, which can result in further blocking of blood flow.  Calcium build up 
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usually occurs over time, and the sites of the initial binding suggest that the 
repeated damage from flexing may be the initiating factor13.  Abnormal valves, such 
as congenital bicuspid aortic valves, are associated with a higher risk of calcification, 
due to its abnormal anatomy and function. 
The other abnormal valve function that can result in complications, aside 
from stenosis, is valve regurgitation.  Regurgitation is caused by incompetence in 
the valve in which the valve does not close fully, allowing back flow of blood into the 
ventricle.  Regurgitation, like stenosis, can be caused by calcium build up or from a 
congenital defect in the valve.  Patients who have regurgitation usually tolerate it 
well and may never need to seek treatment, but they may eventually experience 
ventricular hypertrophy13.  Patients who have diseased heart valves can relate their 
symptoms to that of the early signs of heart failure, which can also be an end result 
of a diseased heart valve.  Thus, if left untreated, a diseased heart valve can be a fatal 
condition.  Therefore, treatments should be sought to replace the diseased valve 
before late stage heart failure begin to occur. 
1.4 Current valve treatment options 
Surgical replacement of a diseased aortic valve Patients who have diseased 
heart valves can relate their symptoms to that of the early signs of heart failure, 
which can also be an end result of a diseased heart valve.  Thus, if left untreated, a 
diseased heart valve can be a fatal condition.  Therefore, treatments should be 
sought to replace the diseased valve before late stage heart failure begin to occur.  
There are two kinds of procedures that physicians use to repair or replace the 
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diseased valves.  Physicians have the choice between using a minimally invasive 
procedure, such as a balloon valvuloplasty, to repair the valve and a surgical 
procedure to replace the valve entirely with a mechanical or bioprosthetic valve. 
1.4.1 Minimally invasive repair of diseased valves 
Stenosis of the valves can be diagnosed rather easily through the use of a 
stethoscope in the presence of a murmur of the valve.  Once the diseased valve is 
discovered, it can be evaluated and monitored through the use of an 
echocardiogram (echo).  Once the diseased valve reaches a point of concern for the 
physician, the valve can possibly be repaired in one of the few following ways, if the 
valve is not fully dysfunctional.  
The cardiologist can use cardiac catheterization to perform balloon 
valvuloplasty in order to repair a diseased valve.  The balloon valvuloplasty is a 
comparatively simple procedure to perform, seen in Figure 10.  This method is 
appealing due to its minimal invasive nature and thus the minimal recovery time 
and stress it puts on the patients.  Unfortunately, this balloon valvuloplasty is not 
very effective in the long term, often resulting in restenosis of the aortic valve within 
a year of the procedure15, but has been shown to be more effective in the mitral 
valve stenosis.  Thus, the balloon valvuloplasty should be seen as a method to 
relieve symptoms, but not as a permanent resolution to the underlying disease. 
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Figure 10: Balloon Valvuloplasty.15 
1.4.2 Surgical replacement of diseased valves 
In the event the stenosis of the valve becomes advanced and symptoms 
become dangerous, the cardiologist may elect to proceed with a surgical 
replacement of the stenotic valve.  There are two major types of heart valve 
replacements: mechanical valves and bioprosthetic valves.  Each type of offers its 
own advantages and disadvantages, and thus it is not always clear which type is 
more suitable for the treatment of the patient with valve disease.  This choice 
involves a balance of the inherent advantages and disadvantages that each valve 
replacement type has to offer.  
Mechanical valves are well known to be extremely durable, due to their 
excellent mechanical properties, thus decreasing the need for a future surgery to 
replace due to wearing out16.  With that inherent advantage comes some major 
disadvantages though; the mechanical valves are thrombogenic, which means that 
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the patient will need to be on anticoagulants for the rest of their life and will be at an 
increased risk of hemorrhaging. 
The bioprosthetic valve offers the patient a non-thrombogenic alternative to 
the mechanical valve, as it is more biocompatible16.  Another advantage that the 
bioprosthetic heart valve offers over the mechanical valve is its ability to be utilized 
in a newer surgical method, known as the transcatheter valve replacement (TVR).  
This procedure allows for the valve replacement to be surgically put into place 
through a catheter, and therefore is minimally invasive and offers all of the 
advantages of a minimally invasive procedure.  This procedure is most commonly 
performed on aortic stenosis, and is known as TAVR in this case.  This is procedure 
is performed fairly similar to the cardiac catheterization described prior, but on the 
end of the catheter there is a valve that has been engineered to push the old valve 
out and replace it, either by balloon or by spring, shown in Figure 11. 
Figure 11: Transcatheter aortic valve replacement (TAVR) procedure17 
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Again, with this advantage comes a distinct disadvantage, as the 
bioprosthetic valves only last about 10-15 years, due to the material undergoing 
structural deterioration16.  Part of this structural deterioration that comes with the 
bioprosthetic heart valves is its tendency to calcify, or re-calcify in the cases of CAVD 
patients, which leads to the restenosis of the valve and thus the need for another 
valve replacement.  This calcification of the bioprosthetic heart valves is a main area 
of concern for current tissue engineering, in order to engineer a bioprosthetic 
replacement valve that is both durable and non-thrombogenic. 
1.4.3 Limitations of the current valve replacements 
Calcification of the implant is not a problem that only affects bioprosthetic 
heart valves, but one that has been affecting a variety of cardiovascular implants, 
such as the aortic homograft and tri-leaflet polymeric valve prosthesis. 18  This 
pathological pathway has caused the dysfunction of these different medical devices 
prematurely through the buildup and mineralization of calcium phosphate 
molecules on the surface.  This calcification can lead to the dysfunction of these 
replacements by either causing mechanical dysfunction (a failure in opening and 
closing), an obstruction of the vasculature, or the calcium deposits breaking off or 
causing an embolism.18  There are many steps in the pathology of the calcification of 
a bioprosthetic tissue replacement, which lead to the degenerative nature of the 
valve, shown in Figure 12.19  This process was initially thought to be unregulated, 
but it is now thought to be a regulated event through the use, and loss of function of, 
mineralization inhibitors.  This physiological process is similar to that of the 
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mineralization of bone.  This calcification deposition and degradation occurs in the 
replacements due to the calcium in the blood binding to the mechanically damaged 
cell fragments of the bioprosthetic tissue.  This calcium deposition is especially 
problematic for the bioprosthetic tissue due to the chemical cross-linking with 
glutaraldehyde fixation.  This fixation disables the calcium pump in the cells, which 
in healthy cells allows calcium ions to be pumped out of the ability of cells in the 
tissue to pump calcium out of the cells.  The calcium in the membranes will then 
bind to the phosphate, which results in the buildup, and eventual enlargement of 
calcium crystal molecules.  This is crystal growth ultimately stiffens and weakens 
the tissue until dysfunction or failure begins to occur. 
Figure 12: The hypothetical model of how calcification occurs in bioprosthetic valves..19 
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Some further regulatory investigations suggest that this calcification may be 
regulated by noncollagenous matrix proteins, such as osteopontin, osteonectin, and 
osteocalcin.19  Osteopontin is an active calcium binding phosphoprotein that has a 
high affinity to hydroxyapatite, a key component in bone formation.  This and high-
density cholesterol (HDL) function as inhibitors for calcium binding.  Other factors 
that have been demonstrated to have a regulatory role in calcification of 
bioprosthetic heart valves include TGF‐α, and tenascin-C. Evidence suggests that 
hypercholerolemia may play a role as a risk factor, due to the large amount of low---
density cholesterol (LDL) in the blood causing inflammation.  The pathway for 
vascular cell calcification was mimicked in genetic studies in transgenic mice using a 
metalloproteinases (MGP) gene knock out, or inactivation of the osteopontin gene, 
and it was observed that severe calcification of the blood vessels occurs.  This 
confirms that the osteopontin gene is essential to the regulation of mineralization, 
and also that calcification can be inhibited through the inhibition of matrix 
remodeling metalloproteinases. 
24 
Figure 13: (A,B)H&E stains of calcified leaflets.  (C)Masson trichrome stain of a non-calcified leaflet.20 
Another potential pathway of calcification that has been postulated is that of 
the inflammatory and immune processes upon valve replacement19.  This pathway 
has gained some ground due to antibodies specific to valve components being 
detected in some patients with valve dysfunction and failed tissue having 
mononuclear inflammation.  Although these two components provide some a hint 
that they play a role in the calcification process, there have been studies in nude 
mice (T-cell function knocked out) that still exhibited calcification morphology, 
which points to the fact that the immune and inflammation responses may be a 
secondary response to the valve damage caused by calcification, rather than the 
causal factors of failure.19 
1.4.4 The ideal engineered valve replacement 
Tissue engineering is a field that deals with the creation of tissue based 
“scaffolds” in order to replace or repair a diseased structure in the body.  This 
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process is can be done in a number of different ways, but the ultimate goal is to 
create a scaffold that has the same or similar mechanical, chemical, and structural 
properties of the original organ or tissue.21  In order to create the ideal functional 
tissue-engineered scaffold the following objectives must be met, as proposed by the 
leaders in the musculoskeletal field:22 
1. Define the functional success of the tissue before implementing
2. Understand biomechanical properties of both the engineered and native tissue
3. Establish design requirements of the scaffold
4. Understand microenvironment of the cells within the scaffolds
5. Control cellular differentiation through biophysical stimuli
6. Provide a permanent solution as a treatment
These objectives must be met for the construct to be considered a viable 
option in implementation.  One method of creating the ideal scaffold has be 
proposed to be achieved by using biological scaffolds, such as repurposing a piece of 
animal tissue that has been decellularized and then recellularized with a cell type 
that have no cytotoxicity and illicit no immunologic response.  These scaffolds 
would allow for the proper biochemical and mechanical signaling for the culture of 
the cells that are seeded onto the scaffold because they are derived from the original 
tissue type.  Other methods include creating a scaffold from a polymer, synthetic or 
natural, to mimic the structure of the original tissue. 
The ideal tissue engineered valve would provide three components that 
would work together to replace or repair the diseased tissue.  These three 
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components are the physical structure of the tissue, the cellular components, and 
the chemical properties and these components would be as similar as possible to 
that of the native tissue before disease.  In addition to these three components, the 
ideal tissue engineered valve should not be cytotoxic, not illicit an immunologic 
response, have a small diffusion barrier to allow nutrients to diffuse into the 
scaffolds, and the control of the degradation time of the scaffold.21  This last 
characteristic is very important because it allows for the proper amount of time for 
integration of the scaffold at both the cellular and tissue levels. 
1.4.5 Adipose stem cells in tissue engineering 
Tissue engineering, or regenerative medicine, relies on many different 
variables in order to repair or replace a damaged organ.  Despite the recent 
advances in material science, which have resulted in the ability to fabricate fully 
biocompatible scaffolds that allow for cell infiltration and angiogenesis, a 
challenging aspect of this multidisciplinary endeavor remains to be the availability 
and utilization of stem cells.  In order to find the ideal stem cell, the desired stem cell 
should meet the following guidelines, described by Gimble et al. The stem cells must 
be found in abundance, acquired with a minimally invasive procedure, have multiple 
cell lines that the cell can differentiate into, is able to be transplanted safely into 
both autologous and allogenic hosts, and can be manufactured within the Good 
Manufacturing Practice guidelines23.  These guidelines rules out most cell types, due 
to their inability to be harvested efficiently, but a particular cell type stands out as 
one that falls within the guidelines described above.  This cell type is the adipose 
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derived stem cell and they are isolated through the tissue harvested from 
liposuction, meaning there is plenty of available tissue due to the increasing 
popularity of the liposuction procedure.  These cells are also capable of being 
differentiated into many different cell lines, as seen in Figure 14 below. 
Figure 14: Possible lineages of adipose-derived stem cells.24 
One of the major aims of tissue engineered scaffolds is to create a scaffold 
that is fully populated with cells prior to their implantation.  The problem with the 
seeding of these scaffolds is that the cells like to adhere to the surface of the tissue, 
but usually cannot penetrate inside the extracellular matrix.  There are a few 
different techniques that have been developed in tissue engineering to try and 
uniformly seed the scaffold with cells throughout its entire thickness.   
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1.4.6 Limitations and challenges in valve tissue engineering 
Obviously, there are some strict guidelines and regulations that come with 
the design of a tissue engineered heart valve. But in today’s current prosthesis 
regime, there is no real “gold-standard” for the replacement valve, due to either the 
mechanical or the bioprosthetic valve coming at a significant cost, the increase of 
complications. Thus the ultimate challenge in any tissue-engineering field, and it holds 
true for the fabrication of bioprosthetic valves, is to create that “gold-standard” with 
the least amount of complications. There is a limitation, therefore, to the materials 
that are most likely to be durable and sustainable inside the body, while 
maintaining a non-thrombogenic effect. 
One of the biggest challenges is presented not by the valve itself, but by the 
exposed aortic wall. The aortic wall is much harder to treat with anti-calcification 
methods, due to the differing effects of the pretreatment methods19.  Thus a material 
must be found that can be effective on both the aortic wall and the valve itself, or a 
combination therapy must be utilized to gain the beneficial effects necessary to 
make the new bioprosthetic valve a viable option to the alternative that is already 
on the market. 
Another challenge that comes inherently with working with the heart valve is 
that, in order to gain valuable and meaningful data, a 15 to 20 year clinical study 
must be completed before any conclusions can be drawn, and therefore the 
bioprosthetic valves that are on the market are between 15 to 20 years behind the 
current research.  There is recent literature that has shown a recent shift to the 
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study of hydrogels. This research is in its early stages, and therefore there are very 
little clinical results to draw conclusions from the hydrogel paradigm at this time, 
but they do offer a promising and exciting future for the of valve tissue engineering, 
specifically when it comes to the inhibition of calcification. 
The future of current research in bioprosthetic heart valve replacements 
seems to be headed in the direction of modifications of the current bioprosthetic 
model.  These modifications must first be tested in clinical settings, which takes a 
large amount of time to research.  Once the calcification of the modifications have 
been sufficiently researched, there seems to be a shift towards the use a multi-
material valve paradigm, possibly coupled with the use of another anti-calcification 
therapy in order to maintain the structural and mechanical properties necessary to 
avoid primary failure of the bioprosthetic valve replacement, while still eradicating 
the need to replace the valve in 10 to 15 years due to the degradation and restenosis 
from calcium deposition. 
1.5 Hydrogels in tissue engineering 
Hydrogels have been utilized in a variety of medical applications over the last 
60 year.  The first documented use of a synthetic hydrogel was in 1954, when 
Wichterle and Lim developed a soft contact lens.25  Sense then, hydrogels have been 
applied to plenty of different technologies across multiple disciplines, such as 
hygiene products, agriculture, food additives, and biomedical applications.   
Hydrogels are becoming especially popular when it comes to designing 
scaffolds in tissue engineering and regenerative medicine for a variety of reasons.  
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These hydrogels are capable of replicating the structure of the extracellular matrix 
of the original tissue.  The hydrogels are also appealing due to their ability to be 
synthesized in mild conditions and therefore they are relatively easily to fabricate.  
The cause for the shift focus to hydrogels as scaffolds in the tissue engineering field 
is due to the ease of fabrication and the minimally invasive nature of the application 
of these hydrogels.  Some of the major uses for the hydrogels include drug delivery, 
growth factor delivery, and cell delivery to the site of injury.  These scaffolds can 
either be created from natural or synthetic materials to try and mimic the native 
tissue. 
The design and material selection for a tissue engineered scaffold is 
dependent on the desired application of that scaffold.  The goal of most of these 
scaffold materials is to replicate a natural structure in the body, such as the 
extracellular matrix, in order to replicate the structural and mechanical properties 
of the native tissue that is being replaced.  Unfortunately, the solid scaffold 
structures are usually synthesized in an environment that results in an acellular 
scaffold, either through the decellularization of a natural construct or the fabrication 
of a polymer structure in severe conditions.  This factor makes the incorporation of 
viable cells onto the scaffold exceedingly difficult to achieve.  In order to achieve the 
seeding of cells onto the desired scaffold, there has been a shift to the use of a highly 
hydrated scaffold, known as a hydrogel.  These hydrogel scaffolds can be composed 
of either natural-derived materials, synthetically derived materials, or a composite 
hydrogel that is composed of both natural and synthetic materials.  The hydrogels 
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have many advantages over the traditional scaffold due to the properties gained 
through their highly hydrated structure and mild conditions during their 
synthetization method, while potentially maintaining similar mechanical and 
structural properties to that of tissue and the extracellular matrix.   
Hydrogels are three dimensional hydrophilic polymer constructs that have 
been imbibed with large amounts of fluids and crosslinked, which allow the 
hydrophilic hydrogel to be water-swellable without becoming water soluble.  These 
hydrogels most closely resemble soft tissue and are usually made up of components 
that are either similar to or derived from native tissue components, such as the ECM. 
1.5.1 Current hydrogels in tissue engineering 
The strategies for creating a hydrogel for tissue engineering applications 
vary based on the both the desired application and the type of materials available.  
The desired material is dependent on the type of properties that the target tissue 
require.  Materials that are commonly used for scaffolds, while FDA approved 
mechanically strong, can be hydrophobic and created in very harsh conditions 
making the incorporation of cells into the scaffold impossible.  However, hydrogels 
can be synthesized in much milder conditions and therefore can serve as a great 
alternative to traditional scaffolds.  These hydrogels, both natural and synthetic, can 
take the place of the commonly derived scaffold materials when the entrapment and 
incorporation of viable cells are required. Hydrogels are made up of overly hydrated 
polymers, resulting from the incorporation of hydrophilic polymer chains into the 
scaffold.  This leads to hydrophilic scaffold materials and in turn the incorporation 
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of viable cells into the scaffold becomes possible.  There are many different types of 
hydrophilic polymers that are used to form hydrogels and hydrogels can be created 
from either synthetic and naturally derived materials, or a composite material 
comprised of both. 
1.5.2 Classification of hydrogels 
Natural derived materials can be a desirable material to form hydrogels for 
tissue engineered scaffolds due to their naturally occurring prevalence in the human 
body.  These naturally occurring polymers include agarose, alginate, collagen, 
chitosan, fibrin, gelatin, and hyaluronic acid, which are used based on the fact that 
they either naturally occur in the extracellular matrix or contain macromolecular 
components similar to the ECM. 
Collagen specifically is a very attractive material for the use in these 
hydrogels, due to its abundance in mammals as the main protein occurring in the 
ECM.  To date, there have been 28 different types of collagen discovered, and each 
type of Collagen is composed of three polypeptide chains, which wrap around each 
other, binding using hydrogen and covalent bonds, to form a triple-helix structure 
that is shown in Figure 15.  Another reason collagen is a desirable scaffold material 
is the fibers have the ability to self-aggregate into the three stranded structure and 
form stable fibers.  Collagen degradation is relatively easy to control through the use 
of collagenase, allowing its incorporation into an engineered hydrogel fairly easily 




Figure 15: Formation of the triple helix structure of collagen26 
Other materials that have been investigated as possible hydrogel scaffold 
materials include hyaluronic acid and chitosan, due to their structural similarities to 
that of naturally occurring glycosaminoglycans (GAGs).  These GAGs are found in 
every living mammalian tissue and are important to the wound healing process of 
diseased tissue.  The degradation of these materials are also easily controlled 
through the use of enzymes, hyaluronidase and lysozyme respectively.  While there 
are no FDA approved gels for the encapsulation and injection, currently many 
natural hydrogels on the market that have proven cell-viability. 
These naturally derived materials are usually used to replicate the ECM and 
other cellular structures that have degraded through one of the various degradation 
methods, or to otherwise to act as biological carriers for cells into the body.   
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Due to the somewhat unpredictable nature of naturally derived materials, 
sometimes the hydrogel should be derived from a synthetic polymer.  These 
synthetic polymers are much easier for scientists to reproduce with consistent 
mechanical and degradation properties. The gelation properties can also be 
controlled through the manipulation of the specific properties of the  
Three examples of synthetic materials that are commonly used for hydrogel 
applications: PEO, PVA, P(PF-co-EG).  PEO is formed using a photoinitiator and a 
subsequent exposure to UV radiation.  These hydrogels are thermally reversibly, or 
able to be de-gelled, and are also able to be combined with the co-polymers PLA.  
PVA can be used in space filling and drug delivery applications, and can be 
crosslinked with different chemicals or other polymer solutions to form hydrogels.  
However, once it is cross-linked with other polymers it is no longer dissolvable in 
aqueous solutions. 
These synthetic materials are generally used in space filling and drug 
delivery biomedical applications.  This is due to the materials’ ability to be 
controlled using crosslinking or combining with other polymers.  The major 
advantage of these synthetic materials is their ability to be controllably combined 
with other polymers for delivery into the body or otherwise change the properties 
of the formed hydrogel.  However, these materials are not advantageous for cell 
delivery applications due to their harsh fabrication conditions 
In order to achieve the desired properties required for certain biomedical 
applications, some of these hydrogel materials need to be combined.  The hydrogels 
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are labeled composite hydrogels and can be a mixture of synthetic and natural 
derived material, synthetic with another synthetic material, or natural and another 
natural material.  One specific example of a composite hydrogel is the combination 
of hyaluronic acid with collagen.  This hydrogel is combined for the purpose of 
combining the structural integrity of collagen with the wound healing properties of 
GAGs. 
While the material the hydrogels are derived, or the source material, from is 
a very effective way of classifying and sorting the different types of hydrogels, this is 
not the only way to sort them.  Sometimes certain properties may be desired in a 
hydrogel, meaning that it is very useful to sort the hydrogels based on their other 
properties.  These classifications can include the polymeric composition, 
configuration, type of cross-linking, physical appearance, or network electrical 
charge.27 
1.5.3 General properties of hydrogels 
When designing a hydrogel, there are specific design variables of the 
hydrogel that need to be of concern.  These design variables are contingent on the 
type of application they are being applied to and the environment they are being 
deployed in.  The general properties of the ideal hydrogels are, as defined by 
Ahmed: 27  
1) Highest absorption capacity in saline
2) the desired rate of absorption for the application
3) Highest  absorbency under load
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4) The lowest soluble content (resilience in application) and lowest residual
material post-gelation
5) Neutral pH of end product (post formation of hydrogel)
6) Photo-stability (resistant to chemical change)
7) Degradation without toxicity to surrounding environment
8) Durable in a saline or swelling environment and stable
9) Total non-toxic, odorless, and colorless
10) Re-wetting capability, or the ability to return the original solution if
required
11) The lowest cost material possible
It is impossible to find a hydrogel that incorporates excellence in all of the 
characteristics described above, as some of the characteristics are contradictory to 
each other.  This means that some sacrifices must be made in order to obtain the 
ideal hydrogel for specific applications.  In order to choose the best possible 
hydrogel, one must take into consideration the importance of each characteristic to 
their specific application and then optimize the balance between contradictory 
properties.   
1.5.3.1 Environmental stimuli sensitivity of hydrogels 
Hydrogels precursors are typically made up of a polymer network that has 
been highly hydrate into a solution of the polymer.  In order to have these soluble 
polymers form a solid structure, they must be cross-linked in one of a variety of 
different methods.  The properties of a hydrogel rely heavily on the type of cross-
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linking method.  Using a physical stimuli response will yield a reversible bond in the 
polymer chains, yielding a very weak hydrogel composed of hydrogen bonds.28  As 
shown in Figure 16, the other type of cross-linking method is a chemical stimuli, 
which always results in a strong hydrogel via covalent bonds.  Using these different 
types of cross-linking methods, different properties of the hydrogel can be achieved.  
As previously stated, if a strong hydrogel is desired then a chemical cross linking 
method, such as pH or use of specific solvents.  These hydrogels may be stronger 
than those the physical cross-linking method, but the chemical cross-linking can 
affect biocompatibility and biodegradability.  Thus, sometimes it is desirable to use a 
physical stimuli, which requires no potentially toxic method to cross-link the 
hydrogel. This means it is probably desirable for cell encapsulation than that of the 
chemically cross-linked hydrogels.  The softer hydrogels (formed by physical 
stimuli) also can minimize the irritation to the surrounding tissue caused by their 
introduction to a site of injured tissue.  Ultimately, it is possible to change the 
chemical and physical properties of a hydrogel scaffold by manipulating the method 
of cross-linking of the polymer network. 
These environmental stimuli don’t only affect the way that hydrogels initially 
cross-link and form.  The various stimuli can affect the properties of the swollen 
hydrogel as well.  A thermosetting hydrogel, when in a heated environment, can also 
be swollen to a greater extent by submerging it in the desired fluid to be imbibed in 
the hydrogel.29  This is especially important when proposing to inject a 
thermosetting hydrogel into physiological conditions, because this means the 
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hydrogel, if it has not reached equilibrium prior to injection, will uptake some bodily 
fluid and this will change the porosity of the hydrogel.30 
Figure 16: Various stimulation methods to initiate the swelling of the hydrogel27 
1.5.3.2 Porosity and microarchitecture 
The porosity of a tissue engineered scaffold is very important for tissue 
regeneration.  Due to their swollen structure hydrogels have the advantageous 
characteristic of having an increase in the porosity of their structure, while 
maintaining the structural components of the extracellular matrix.31  This increased 
porosity is beneficial to the biological performance of the tissue because it allows for 
a beneficial impact on their diffusion of nutrients and oxygen.  This allows for a 
superior environment to the traditional tissue engineered scaffold, because this 
environment will allow for local angiogenesis to occur, which is required for 
vascularization.30  The porosity of these hydrogels are also controllable through the 
swelling or cross-linking of the hydrogel, as well as the addition of electrospun 
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fibers or freeze-drying the scaffold.  This is very important because different 
porosities are useful for different applications in specific tissue regeneration.  The 
optimal pore sizes for neovascularization and fibroblast growth is 5-15μm, adult 
skin tissue is 20-125μm, 100-350μm for bone regeneration, and 500μm for rapid 
vascularization.30  Thus, the larger pores of hydrogels can be used for different 
applications in biomedical engineering for designing scaffolds.  The voids caused by 
the large pores can be filled with medication that can be used for drug delivery.  Due 
to the hydrogels degradation, usually by hydrolysis, a drug can be controllably 
delivered over time using the encapsulation of the drug in the hydrogel.27  This 
porosity property is also useful for cell-encapsulation.  
1.5.4 Importance of rheological properties for cell encapsulation 
When trying to inject a cell seeded solution through a small diameter needle, 
the shear stresses can have a large effect on the viability of the cells.  This is due to 
the cells lack of protection to the shear stresses, which can induce apoptosis in 
cells.32 The use of a hydrogel in cell encapsulation becomes much more important 
when injecting, because of the hydrogel’s ability to protect the cells from the shear 
stress, due to their high viscosity.33  Most naturally occurring hydrogels also exhibit 
a rheological characteristic known as stress-thinning.  This property is important to 
the injection method because the viscosity of the hydrogel decreases as it is 
subjected to the shear stress from the wall of the needle, leading to the lubrication of 
the needle from the less viscous form of the hydrogel, allowing the rest of the 
hydrogel to flow through the needle with less resistance.  This further protects the 
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cells encapsulate from the stresses of the needle, allowing for a high viability of 
injection.34 
1.5.5 Mechanotransduction and cellular interactions with hydrogels 
Most hydrogels can be formed at mild, physiological condition when 
compared to traditional scaffolds developed in tissue engineering.  For this reason, 
hydrogels are regarded as a very promising material for encapsulating cells in the 
regenerative medicine community.  Some specific characteristics of hydrogels that 
are particularly crucial to cell survival on a scaffold are the following:   
1. Ability to be remodeled by cells35 
2. Permeability to nutrients, oxygen, and metabolic waste36 
3. Ability to mimic the ECM structure of natural tissue35 
4. Viscoelastic tissue properties37 
One of the most important characteristics of the cell-hydrogel interaction is 
the ability of the cell to take the hydrogel scaffold and restructure it into a tissue-like 
structure.  This behavior is imperative to the tissue growth and the repair of 
damaged tissue.  The mechanical interactions with the hydrogel result in the 
embedding of the cells into the hydrogel is the mechanism by which these cells 
remodel, as can be seen in Figure 17.35  For this reason, hydrogels have been used as 
3-dimensional constructs for the study of how the cell interacts with remodeling, 
repair, and regeneration of damaged tissue, based on the biochemical and 
mechanical stimulation of the environment surrounding the cells. 
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Figure 17: Cellular interaction with the hydrogel35 
The ability of these scaffolds to be viable and remodel makes them 
potentially ideal scaffolds.38  The ability for the cells to remodel the hydrogel 
scaffold lies within the cell surface receptors called integrins.35  These integrins 
allow the cells to bind to ligands inside the hydrogel, those on the collagen strands, 
and initiate remodeling.  These ligands are available on collagen and fibrin, though 
not on other hydrogels such as those made from agarose and alginate.  The 
morphology of those cells that have attached is different than those that have not 
initiated attachment.  In cells that have adhered to the ligands of the hydrogel, there 
is a distinct spread morphology.  Those cells that have been encapsulated in 
hydrogels without available binding sites cannot adhere, and therefore do not 
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exhibit this spread morphology.  Instead, they appear rounded and lack visual fiber 
attachment throughout.39  
The cellular adhesion throughout the scaffold is not the only type of 
stimulation that leads to proper cell activity for cellular regeneration.  
Mechanotransduction, or the effect of mechanical forces on cellular behavior, has 
proven to be very important in the correct cell activity.40  The application of these 
forces change the cytoskeleton structure, leading to activation of ion channels and 
phosphorylation. The opening of the correct ion channels leads to the signaling 
molecules being released, signaling correct pathways. These forces can be replicated 
in vitro using a bioreactor, using a different type of bioreactor based on the types of 
forces desired to be replicated.41 
1.5.6 Applications for hydrogels in tissue engineering 
1.5.6.1 Hydrogels used for drug delivery and cell encapsulation 
The cell delivery therapy considers the importance of the presence of 
healthy, living cells at the target site but it does not solve the problem of cellular 
retention.  Injectable hydrogels were proposed to be the solution to this problem, 
allowing for the cells to bind to the hydrogel.42  Some of these hydrogels are 
naturally derived from a decellularized version of the tissue that the hydrogel is 
being applied to, such as decellularized myocardium used as a scaffold for ischemic 
myocardium therapy.  Other hydrogels are made from synthetic materials, such as 
Poly-acrylic acid hydrogels, and composite hydrogels that are a combination of two 
different types of materials. 
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The synthetic hydrogels give the distinct advantage of control of the 
components in order to control and optimize the properties of the gel.  These gels 
can be manipulated to have stronger mechanical properties than naturally derived 
gels and therefore have been a strong interest in cardiovascular tissue engineering.  
While these gels show promise in multiple applications, such as drug delivery and 
mimicking the extracellular matrix, a large majority of these materials have 
drawbacks in their biodegradability or stimulation of the inflammatory response.   
When using a material for cell delivery, the FDA requires at least 70% 
viability upon completion of the study.32  If this viability is not achieved, other 
cytotoxicity testing is required to test for potentials cytotoxins in the material 
causing cell death. 
Figure 18: Strategy for encapsulating cells inside a hydrogel scaffold43 
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1.5.6.2 Hydrogels used for tissue replacement or regeneration 
In designing a hydrogel that can serve as a tissue replacement or to 
regenerate damaged tissue, there are a few design variables that are advantageous 
for those applications.  The following characteristics of a hydrogel are particularly 
advantageous in the use of artificial muscles: the hydrogels must be biocompatible, 
have material properties similar to the tissue that they are simulating, non-
biodegradable, able to have its properties manipulated chemically, have an easily 
adjusted shape, and be a low-cost to manufacture.  Furthermore, these gels must 
have the ability to expand and contract under the pressures that the native 
biological tissue is subject to in physiological conditions.   
1.5.7 Cardiac repair via injectable hydrogels 
There has been a shift in recent research to the use of non-invasive 
treatments to facilitate the repair of damaged cardiac tissue.  This shift has led to 
much research in the field of hydrogels.  The need for these hydrogels arose from 
the lack of effective treatments, with the inability to treat ischemic cardiac tissue 
post myocardial infarction a large motivating factor.  The damaged tissue has been 
treated via a combination of pharmaceutical agents, interventional therapies via 
medical devices, or heart transplantation.  Heart transplantation was the only truly 
effective of these techniques in the treatment of these diseases, while the other two 
only work to optimize the function of the remaining living tissue.44  Due to heart 
donors being in very short supply, the need for an alternative treatment method is 
very apparent.   
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This alternative treatment needs to allow for growth and repair of the tissue 
without the need to remove or replace the damaged tissue.  One of the proposed 
treatment methods to solve this need is cell delivery via injection of the appropriate 
cell type or stem cells at the site of the damage, thereby providing the proper 
cellular components to the ischemic tissue.  Unfortunately, this procedure has a low 
yield of cell retention at the target site and therefore is not a highly effective 
procedure.  However, this idea gave rise to the idea of cellular therapy via a different 
delivery method such as delivery via drugs or delivery via cell-encapsulated 
hydrogels. 
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CHAPTER 2: PROJECT AIMS 
AND RATIONALE 
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The valve replacements that are currently on the market have many draw backs to 
their use, including the lifelong need for anticoagulants, or the wearing down of the 
replacement.  There is also usually an invasive surgery that is required, which results in  
There are currently many endeavors to create the ideal heart valve replacement through 
the use of tissue engineered constructs, using various methods.  However, there is a 
growing need for a non-invasive treatment method, designed for the high risk patients 
that are not strong candidates for a valve replacements.  The motivation behind my 
project is to create a new material that will be injected non-invasively, in order to act as a 
delivery method for stem cells to the diseased or damaged site on an aortic valve. 
The specific aims of my project to contribute to the landscape of tissue 
engineering efforts to create an effective and long-lasting treatment for heart valve 
disease include: 
1. To fabricate and optimize a novel hydrogel scaffold derived from
decellularized porcine aortic cusp tissue for aortic valve applications
2. To achieve and optimize the encapsulation of the hydrogel scaffold
through seeding of hADSCs




CHAPTER 3: MATERIALS AND METHODS  
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3.1 Study 1: Fabrication of hydrogel using decellularized aortic cusps 
3.1.1 Collection and harvesting of porcine aortic cusps 
Porcine hearts were received from Snow Creek Meat Processing immediately 
after death and put on ice.  The hearts were then put in a bucket of ddH2O on ice 
while setting up the tools for harvesting.  The aortic root was isolated from the rest 
of the heart and the rest of the heart was disposed of in biohazard waste.  The major 
vessels, atria, fat and ventricular muscle were removed from the heart so that only 
the aortic root and mitral flap (5-10 mm past the base of the cusp) remained.  Figure 
19 shows the appropriate size of the harvested aortic root, keeping the aortic root 
and cusps intact with no damage to the desired tissue. 
Figure 19: Harvested aortic root for decellularization. 
(Left) Side view of the aortic root showing the mitral flap and 




3.1.2 Decellularization of porcine aortic cusps by immersion 
Each root was decellularized in detergents already shown to be effective in 
decellularizing cusp tissue, while maintaining its extracellular matrix structure.  The 
tissue was briefly washed in changes of distilled water and stirred in 0.02% sodium 
azide overnight. The tissue was then rinsed in ethanol and water, stirred again in 
0.02% sodium azide overnight, and rinsed in phosphate buffered saline (PBS) for 
one day.  The aortic roots are immersed in a DNase/RNase solution at 37 oC for two 
days, and then rinsed with PBS for one day.  The aortic roots were sterilized using 
0.1% Peracetic acid and rinsed PBS for one day, then the cusps were dissected to 
remove the remained of unwanted tissue so only cusps remain, shown in Figure 20. 
 
 
Figure 20:  Aortic Cusp Harvesting 
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One cusp was removed, processed, sectioned at 5 µm and stained with 
hematoxylin and eosin (H&E) to confirm the absence of cells.  Fresh aortic cusps 
were also processed, sectioned at 5 µm and stained for H&E as a reference.  
Following the decellularization process, the aortic cusps were deconstructed and 
lyophilized using the following procedure to create a powder. 
3.1.3 Decellularization verification of aortic valve tissue 
Sufficient decellularization was first verified with agarose gel electrophoresis 
and histology using hematoxylin and eosin, DAPI fluorescent, and Movat’s 
Pentachrome stains.  Fresh and decellularized samples were fixed in 4% 
paraformaldehyde overnight (24 hours maximum) placed in a processing cassette, 
paraffin-embedded using the automatic tissue processor according to the following 
preset protocol.   
• 10% buffered formalin (1 min) at 37oC
• 10% buffered formalin (1 min) at 37oC
• 70% ethanol (15 min) at 37oC
• 80% ethanol (15 min) at 37oC
• 95% ethanol (15 min) at 37oC
• 95% ethanol (15 min) at 37oC
• 100% ethanol (15 min) at 37oC
• 100% ethanol (15 min) at 37oC
• Xylene (5 min) at 37oC
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• Xylene (10 min) at 37oC 
• Paraffin (15 min) at 60oC 
• Paraffin (15 min) at 60oC 
• Paraffin (15 min) at 60oC 
• Paraffin (15 min) at 60oC 
Samples were then stored in a warming drawer and the tissue samples were 
embedded in blocks of hot paraffin on the back of the cassettes, cooled using a cold 
plate at -5°C and then transferred into a bucket of ice water for sectioning.  The 
embedded samples were then sectioned at 10 µm using a microtome and the 
sectioned paraffin ribbons were transferred to a water bath at 44°C and carefully 
mounted on glass microscope slides by moving the slides underneath the ribbons 
without disturbing air bubbles that build up on the bottom of the water bath.  The 
slides were then patted dry using a kimwipe, then put in a plastic slide holder and 
transferred into an oven at 60°C to bake the tissue sample onto the slide.  The slides 
were then deparaffinized in xylene for 5 minutes, rehydrated in a succession of 
dilutions of ethanol and are now prepared for various stains, including: hematoxylin 
and eosin (H&E), DAPI fluorescent, Movat’s pentachrome, and Masson’s trichrome. 
3.1.3.1 Histology: Hematoxylin & eosin staining and imaging 
The following protocol for H&E staining was established and verified by the 
Clemson University Bioengineering Department.  After the rehydration series from 
above, the slides are rehydrated in ddH2O, stained in hematoxylin for 7 minutes, 
rinsed with ddH2O and tap water, and stained for eosin for 45 seconds.  The samples 
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are then dehydrated in a series of concentrations of ethanol and xylene.  
Immediately put coverslips on the microscope slides using paramount medium to 
glue the coverslips on allow to dry.  The samples were then imaged using a light 
microscope at 10X, 20X, and 40X magnifications. 
3.1.3.2 Histology: DAPI nuclear staining and imaging 
After the rehydration step, the slides are rinsed in ddH2O and mounted using 
Vectashield mounting slips with DAPI fluorescent medium.  The slides are place in a 
closed slide holder in order to keep slides in the dark, and placed in refrigerator 
(4°C) and allowed to dry.  The slides are then imaged in the dark using a fluorescent 
bulb on a light microscope and a blue fluorescent filter. 
3.1.3.3 Histology: Masson’s Trichrome and imaging 
After the rehydration step, slides are rinsed in ddH2O and fixed using 
Boulin’s fixative at 56°C for one hour.  Samples were rinsed with running tap water 
for 10 minutes and then stained with Weigert’s iron hematoxylin working solution 
for 10 minutes.  Samples were again rinsed with warming tap water for 10 minutes, 
washed in ddH2O and stained with Biebrich scarlet-acis fuchsin solution for 10-15 
minutes.  After the Biebrich staining, the samples were washed in ddH2O and 
differentiated in phosphomolydic-phosphotungstic acid solution for 10-15 minutes.   
Without rinsing, sections were transferred to aniline blue solution for 5-10 minutes 
and then rinsed with 1% acetic acid solution for 2-5 minutes.  Distilled water was 
then used to wash the samples, dehydrated in ethanols, and cleared in xylene.  
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Coverslips were then mounted using paramount medium and the samples were 
then imaged using a light microscope at 10X, 20X, and 40X magnifications. 
3.1.3.4 Histology: Movat’s Pentachrome and imaging 
After the rehydration step, slides are rinsed in ddH2O and placed in 1% 
Alcian Blue for 20 minutes.  The samples are then washed using running tap water 
for 3 minutes and place in alkaline alcohol (pH=8) for 2 hours.  The samples are 
washed again with running tap water for 10 minutes, then rinsed in 70% alcohol, 
placed in Resorcin Fuchsin Working Solution for 16 hours.  The samples were 
washed in running tap water for 10 minutes, rinsed in ddH2O, and placed in 
Weirget’s Hematoxylin Working Solution for 15 minutes.  Tap water and ddH2O 
were used to rinse again and the nuclei are then differentiated using Woodstain 
Scarlet—Acid Fuchsin Solution for 5 minutes, rinsed using 0.5% Acetic Acid, and 
differentiated in 5% Phosphotungstic Acid for 10-20 minutes. Again, the samples 
were rinsed in 0.5% Acetic Acid and rinsed thoroughly with 100% EtOH.  Saffron Du 
Gratinais was used for 15 minutes and then the samples were dehydrated in a series 
of dilutions of ethanol and xylene and coverslips were immediately mounted using 
paramount mounting medium.  The samples were then imaged using a light 
microscope at 10X, 20X, and 40X magnifications. 
3.1.3.5 Agarose gel electrophoresis for DNA loss verification  
Both native and decellularized aortic cusps had their DNA purified using the 
Qiagen Kit, following the manufacturer’s instructions for tissue samples.  The 
agarose gel was formed by placing 1% agarose gel in the microwave for 1.5 minutes, 
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cooled to 60°C and 10μl of ethidium bromide is added to the gel.  The gel is then 
poured in the mold and the comb is placed based on the number of combs.  The 
standard and samples were loaded into each well and were run at 100V for 60 
minutes.  The gel was imaged using the ethidium bromide setting on the ChemiDoc 
MP+ BioRad imaging system. 
3.1.4 Powdered aortic cusp preparation 
In order to prepare a sterile powdered aortic cusp tissue, each cusp was first 
shredded into small pieces using sterile scalpel blades.  The tissue was then blended 
using the homogenizer at the maximum speed setting.  The tissue was lyophilized 
and weighed in preparation for the next step, stored in freezer (-20oC) if not 
immediately preparing solubilized tissue solution. 
3.1.5 Preparation of solubilized aortic cusp for gelation 
To generate a gelation form of cusp extracellular matrix, the decellularized 
matrix was solubilized using a method adopted from a previously published 
protocol by K.L.  Christman.42  Pepsin (Sigma P7125, 400 U/mg) and 0.01 M 
hydrochloric acid (HCl) solutions were first used to determine the optimal 
concentration of pepsin to digest the ground tissue matrix.  The ideal pepsin:matrix 
ratio was found to be 1.5:1 (m/v), or 600 units of Pepsin per milligram of aortic cusp 
tissue, and a 10:1 concentration of 0.01M HCl:matrix (m/v) was used.  The matrix 
was allowed to digest for 48 hours under constant shaking, via an orbital shaker, 
until completely solubilized.  The solution was then neutralized to a pH of 7.2-7.6 by 
the addition of sodium hydroxide (0.1N NaOH) and diluted using a 1:10 
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concentration of chilled 10X PBS and 1X PBS to dilute to the desired concentration 
of 6 mg/ml.  The final solubilized matrix was then incubated at 37oC for two hours 
to induce gelation process.  In order to inhibit the gelation of the solutions, keep on 
ice for short term storage store at 4°C until use, for long term storage store in -80°C. 
3.1.6 Preparation of PureCol® hydrogel 
The protocol for preparation was adapted from the Advanced BioMatrix 
manual for PureCol®, Bovine Collagen Solution, Type I (3 mg/ml).  While keeping all 
solutions on ice, add 1 part 10x PBS to 8 parts collagen solution.  The pH was 
adjusted using 0.1 M NaOH to 7.2-7.6, monitored using a pH paper strip.  The final 
volume was brought to 10 total parts with sterile 1xPBS.  To initiate gelation, the gel 
was warmed in incubator (37°C) for approximately 1 hour.   
3.2 Study 2: Characterization of aortic cusp-derived hydrogel 
3.2.1 Thermal gelation of hydrogel 
The thermal gelation was evaluated using a temperature controlled water 
bath, increasing the temperature every 5 minutes from room temperature (25°C) 
until the gelation point is reached.  Gelation was tested using the inversion test, 
where the solutions were inverted inside a micro-centrifuge tube at each time point, 
until the solution was no longer fluid inside the tube. The time of the complete loss 
of fluidity, or full gelation, was recorded for each gel solution. 
3.2.2 Swelling and solubility behavior of the hydrogel 
In order to quantify the swelling behavior and equilibrium water content, a 
swelling behavior assay was performed, adapted from Sanders, 2014.45  Solutions of 
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the hydrogel immaterial were prepared at as described above at a volume of 100 µl 
samples and at three different concentrations of gel; 6mg/ml, 4.5mg/ml and 
3mg/ml of the aortic cusp derived gel and a PureCol® gel.  The hydrogels were 
allowed to form for 24 hours at 37°C, and weighed yielding the initial wet weight 
(Ww1) of each hydrogel.  Each of these hydrogels were frozen at -80°C, lyophilized 
for 24 hours and weighed (Wd1).  The hydrogels were then allowed to swell in an 
excess amount of 1X PBS (pH=7.4) at 37°C for 24 hours.  The excess buffer on the 
hydrogels were then blotted off and the hydrogels were weighed (Ww2).  The 
hydrogels were again frozen at -80°C, lyophilized for 24h and weighed (Wd2).   
Where ρ𝑔𝑔is the hydrogel density and ρ𝑠𝑠 is the density of 1X PBS (1 g/ml).  





Equation 1: Equilibrium Water Content Percentage of Hydrogel45 
  
Equation 2: Calculation of the solubility of a hydrogel 
3.2.3 Collagen content quantification of hydrogels 
The samples were frozen (-80°C) overnight and lyophilized to obtain 10-
15mg of dry weight.  The samples are submerged in 4N NaOH and hydrolyzed at 
120°C for two hours.  Complete the hydrolysis inside a hydrolysis bottle and 
covered in tin foil in order to avoid evaporation of the sample.  Using 1.4N citric 
acid, the solution should be neutralized to a pH between 7.2 and 7.6.  The final 
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volume of the sample is measured and allow the precipitate to fall off before 
analyzing the solution.  Add the 200-μl of the sample into a small borosilicate tube, 
adding one mL of Chloramine T to each sample and the standard, allow to incubate 
at room temperature for 20 minutes. Add 1-mL of the PDMAB solution (p-dimetil-
amino-benzaldehyde, n-propanol, 60% H2SO4) to the samples and standards to 
create the colorimetric binding of the sample.  The samples should be vortexed and 
incubated at 65°C for 15 minutes, again covering with tin foil to avoid evaporation.  
The samples are each then pipetted in triplicate and the standards in duplicate into 
a 96-well plate are pipetted at a volume of 300-μl.  The plate is read using a plate 
reader and the Gen5 software, at an optical density of 550nm.  A standard curve is 
made using the standard readings, and a trend line is created to obtain the 
concentration of hydroxyproline that corresponds to the absorbance reading.  The 
collagen percentage in the tissue is then calculated based on the equation below. 
% 𝐸𝐸𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑖𝑖𝐶𝐶 𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝐶𝐶 =
100 × 𝜇𝜇𝐶𝐶 𝐻𝐻𝐻𝐻𝐻𝐻𝑚𝑚𝐶𝐶 × 𝑉𝑉𝐶𝐶𝐶𝐶 𝑡𝑡𝐶𝐶𝑚𝑚𝐻𝐻𝐶𝐶𝐶𝐶 𝐶𝐶𝑎𝑎𝑡𝑡𝐶𝐶𝑎𝑎 𝐶𝐶𝐶𝐶𝑡𝑡𝑡𝑡𝑎𝑎𝐶𝐶𝐶𝐶𝑖𝑖𝑛𝑛𝐶𝐶𝑡𝑡𝑖𝑖𝐶𝐶𝐶𝐶 × 8.33
𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝐶𝐶 𝑤𝑤𝐶𝐶𝑖𝑖𝐶𝐶ℎ𝑡𝑡 (𝑚𝑚𝐶𝐶)
 
Equation 3: Calculating the percent collagen in a construct from a hydroxyproline assay 
3.2.4 Rheological studies for viscosity of hydrogel 
The viscosity of the aortic cusp-derived hydrogel precursor was tested using 
the Brookfield DVIII Ultra Programmable Rheometer.  One-mL of hydrogel 
precursor was injected onto the CP42 spindle and run using the parameters in 
Figure 21, each ramp being run for 3 minutes, for a total of 15 minutes per 
experiment.  The viscosity of the precursor solution was then first calculated using 
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Equation 4, where F/A=shear stress, η is viscosity and V/h=shear rate. Therefore, 
the apparent viscosity can be found as the slope of shear stress vs. shear rate.  The 
fluid was then fit to a better model, the Power Law model, which is used for fluids 
that exhibit a non-Newtonian behavior.  The viscosity was then compared to 







Ramp 1 1 RPM 1.00 RPM 1.00 RPM 
Ramp 2 2 RPM 3.25 RPM 4.50 RPM 
Ramp 3 3 RPM 5.50 RPM 8.00 RPM 
Ramp 4 4 RPM 7.75 RPM 11.50 RPM 
Ramp 5 5 RPM 10.0 RPM 15.00 RPM 






Equation 4: Equation for viscosity of a Newtonian fluid46 
𝜂𝜂 = 𝑘𝑘𝛾𝛾𝑛𝑛−1 
Equation 5: Power law model for pseudoplastic materials33 
3.2.5 Porosity analysis of aortic cusp hydrogel, decellularized cusp, and 
PureCol® 
The H&E sections were analyzed using the ImageJ software for porosity size, 
number of pores, and overall area of the pores.  In order to do this, the scale was set 
using the scale bar in the image, the threshold was set so the pores appear red 
(Figure 22: Porosity protocol for H&E sections (Figure 22, left).  The feret’s diameter 
(Figure 22, right) was then analyzed of each pore using the software.  The results 
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were transferred into an excel file and averaged across three photos (n=3) for each 
study group.  A student’s t-test was used to analyze the difference in pore size, pore 
number and overall area of the pores across all samples. 
 
Figure 22: Porosity protocol for H&E sections 
3.3 Study 3: Encapsulation of hADSCs onto different hydrogel scaffolds  
3.3.1 hADSCs culture and subculture 
Human adipose stem cells were removed from cryopreservation liquid 
nitrogen and rapidly warmed using a water bath at 37°C.  The cells were transferred 
into approximately 5-mL of fresh, warmed culture media (90% 1x DMEM, 9% Fetal 
Bovine Serum, 1% Antibiotic/Antimycotic) and centrifuged at 12,000 rpm in order 
to achieve a cell pellet.  The culture media was aspirated, the cells were resuspended 
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in fresh, warm culture media and were plated onto a Corning T-175 flask at a 
density of about 5,000 cells/cm2.  Culture media was replaced every 3-4 days. 
In order to subculture the cells, cell were rinsed with warmed PBS, aspirated, 
then trypsin EDTA was used to detach the cells from the flask for 5-7 minutes.  The 
trypsin was deactivated using culture media and the cell suspension was 
transferred to a 50 mL conical tube.  The cell suspension was centrifuge at 12,000 
rpm for 5 minutes to achieve a pellet, the old media was aspirated off, and the cells 
were resuspended the cells in fresh culture media.  The cells were then re-plated on 
T-175 flasks at the desired density. 
3.3.2 Encapsulation of hADSCs onto hydrogel scaffolds 
All steps for this study were performed in sterile conditions.  The aortic cusp 
hydrogel and PureCol® precursor solutions were made as described previously 
(3.1.5) up until the addition of 1X PBS, which was replaced with DMEM culture 
media for this study.  The hydrogel precursor was kept on ice until cells were ready 
to encapsulate.  The cell culture of hADSCs was passaged as described previously 
(3.3.1) and the cells were counted using the cell scepter in order to determine the 
total number of cells.  The cells in culture media were then transferred into the 
hydrogel precursor solutions in order to achieve a cell density of 800,000 cells/mL 
in both of the solutions.  The precursor solutions were then brought to their desired 
concentration using DMEM culture media (6 mg/ml for the aortic cusp derived 
hydrogel and 3 mg/ml for the PureCol® hydrogel).  The solutions are mixed via 
pipette mixing, note that the aortic cusp derived hydrogel is extremely viscous and 
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the pipette tip needed to be cut wider using a sterile razor blade in order to 
successfully pipette.  The hydrogel precursors were plated on a 24-well place at a 
volume 0.5-mL per well using the schematic shown in Figure 23. 
Figure 23 : Schematic for cell encapsulation in hydrogels plating on a 24-well plate. 
Once hydrogels were plated, the well plate was placed in incubator (37°C, 5% 
CO2) for two hours to ensure full gelation.  After full gelation has occurred, 1-mL of 
DMEM culture media was pipetted on top of the hydrogels without disturbing them.  
The culture media was changed every 3 or 4 days, being careful not to disturb the 
hydrogel on the plate.  Images were taking every 24 hours using the ChemiDoc MP+ 
BioRad system for contraction analysis.  This study was run for a total of 24 days. 
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3.3.3 Contraction analysis of hydrogels 
The images taking daily from the ChemiDoc MP+ BioRad system, the images 
were imported into the ImageJ software.  Using the drawing tool in ImageJ, each 
hydrogel was outlined every day and the surface area was taken using the measure 
function.  The scale was based on the known dimensions of a 24-well plate.  The 
surface areas of each test group was averaged and graphed as a function of time. 
3.3.4 LIVE/DEAD cytotoxicity assay 
The media from each well was aspirated in the plate as washed using pre-
warmed 1XPBS.  The Live/Dead assay from Molecular Probes was used to evaluate 
the viability of the cells on each hydrogel after 24 days.  A mixture of 4mM Calcein 
AM, 2mM ethidium homodimer-1 (EthD-1) in 1XPBS was used to stain the wells.  
The well plate was incubated for 20 minutes at 37°C, and then imaged using a 
fluorescent microscope using a green filter for living cells and red filter for dying or 
dead cells.   
3.4 Study 4: Hydrogel encapsulation of hADSCs in varying concentrations 
3.4.1 Encapsulation of various concentrations of hADSCs in aortic cusp 
hydrogel 
All steps for this study were performed in sterile conditions.  The aortic cusp 
hydrogel precursor solution was made at a concentration of 6 mg/mL, as described 
previously (3.1.5) up until the addition of 1X PBS, which was replaced with DMEM 
culture media for this study.  The hydrogel precursor was kept on ice until cells 
were ready to encapsulate.  The cell culture of hADSCs was passaged as described 
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previously (3.3.1) and the cells were counted using the cell scepter in order to 
determine the total number of cells.  Prior to seeding of the cells, 100μL of hydrogel 
precursor was coated onto each well in order to ensure that no cells would adhere to 
the well plate and would stay on inside the scaffold until full gelation took place.  The 
hydrogel precursors were then seeded at the densities described in Figure 24: Cell 
seeding schematic for study 4 Pictures were taken every day using the ChemiDoc MP+ 
BioRad Imager in order to gather the images necessary to do the contractile analysis 
described in the prior study (3.3.3).   
After 13 days, a Live/Dead assay was run on each sample in accordance with 
the protocol described earlier (3.3.4). 
Figure 24: Cell seeding schematic for study 4 
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3.4.2 Contraction analysis of hydrogels 
The images taking daily from the Chemi Doc MP+ BioRad system, the images 
were imported into the ImageJ software.  Using the drawing tool in ImageJ, each 
hydrogel was outlined every day and the surface area was taken using the measure 
function.  The scale was based on the known dimensions of a 24-well plate.  The 
surface areas of each test group was averaged and graphed as a function of time.  A 
student’s t-test was used to analyze the difference in contraction rate across all 
samples at every time point. 
3.4.3 Quantification of glycosaminoglycan content using DMMB assay 
The samples were frozen (-80°C) overnight and lyophilized, dry weights of 
each sample were recorded for normalization.  Sample are digested using 1-mL of 
15mg/ml proteinase K in 30mM Tris Buffer (pH 8.0) for 24 hours at 50°C.  In a 96 
well plate, a 1:24 mixture of the sample and Tris Buffer is transferred in each well 
and was combined with 200 of DMMB reagent (40mM NaCl, 40mM Glycine, 46μm 
DMMB).  A standard was made using a 0.025 μg/μl CS stock solution in Tris-buffer. 
The absorbance was immediately read at 525nm using a plate reader and the Gen5 
software.  Using the standard, the absorbance was related to glycosaminoglycan 
(GaGs) content and the GaGs content was calculated for each sample and normalized 
to their dry weight.  A student’s t-test was used to analyze the difference in 
chondroitin sulfate content across all samples. 
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3.4.1 Viability analysis of LIVE/DEAD images 
The protocol previously described in 3.3.4, live and dead images were 
obtained of each group of seeded hydrogel.  The viability of the cell encapsulated 
was then calculated using the ImageJ program (NIH freeware) and the protocol 
described by Labono.47  The cells were isolated from the image by first turning the 
image to greyscale and then using the threshold feature to only visualize the cells.  
Note, if there was overlap of cells, then the watershed feature was used to isolate the 
cells further.  The image was then turned into a binary image format (Figure 25) and 
analyzed using the analyze particles feature, excluding <10μm2 to reduce the noise 
of the signal analysis.  The number of analyzed particles is the number of cells 
counted.  The percent viability is then calculated based on Equation 6: Viability 
analysis equation.  A student’s t-test was used to analyze the difference in cell 
viability across all samples. 
Figure 25: ImageJ isolation of cells 
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%𝑉𝑉𝑖𝑖𝐶𝐶𝑉𝑉𝑖𝑖𝐶𝐶𝑖𝑖𝑡𝑡𝐻𝐻 = 100 ×
#𝐿𝐿𝑖𝑖𝐿𝐿𝐶𝐶
#𝐿𝐿𝑖𝑖𝐿𝐿𝐶𝐶 + #𝐷𝐷𝐶𝐶𝐶𝐶𝐷𝐷
Equation 6: Viability analysis equation 
3.4.2 Sample preparation for scanning electron microscopy 
Scanning electron microscopy (SEM) was used to image and characterize the 
surface morphology of the hydrogel samples.  Each sample was fixed overnight at 
room temperature using Karnovsky’s fixative (a mixture of 2.5% Glutaraldehyde, 
2.0% Formaldehyde buffered with 0.1M Cacodylic Acid in ddH20).  The samples 
were washed with three changes of 1X PBS and then washed three times with 
ddH2O.  The sample is again fixed, this time incubating in a 0.1% Osmium Tetroxide 
in ddH2O fixative for 30 minutes.  The samples are again washed three times using 
ddH2O.  The samples were dehydrated using the succession of ethanol (electron 
microscopy grade) changes, as follows: 
• 50% EtOH  10 minutes 
• 70% EtOH  10 minutes 
• 85% EtOH  10 minutes 
• 95% EtOH  10 minutes 
• 100% EtOH  15 minutes 
• 100% EtOH  15 minutes 
Upon completion of the dehydration of the sample, the sample is critical 
point dried (CPD) via incubation in excess of Hexamethyldislazane (HMDS) for 20 
minutes.  The HMDS is aspirated off and air dried at room temperature until fully 
dry.  The samples are stored in a desiccator overnight, in order to avoid rehydration 
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of the sample.  Mount the samples on aluminum stubs with double sided copper 
tape and sputter coat the samples for 2 minutes with platinum using the Hummer 
6.2 Sputter Coater, shown in Figure 27, at the Advanced Materials Research 
Laboratory (Clemson University Electron Microscope Facility, Anderson, SC). Store 
in a desiccator until imaging.  The samples are imaged at the AMRL on the Hitachi S-
4800 scanning electron microscope at magnifications ranging from 2,000x to 
50,000x. 
 
Figure 26: Hitachi S-4800 Scanning Electron Microscope 
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Figure 27: Basic Hummer 6.2 Sputter Coater, Anatech USA48 
3.4.3 Collagen fiber diameter analysis of aortic cusp hydrogel 
Using 50,000x images that were obtained from scanning electron 
microscopy, then imported into the ImageJ software.  Using the scale bar provided 
by the image from SEM, the scale is set in ImageJ and the diameter of the individual 
collagen fibers can be measured using the measure tool.  Ten random fibers from 
each sample group were measured and averaged together for comparison.  
3.4.4 Sample preparation for transmission electron microscopy 
Scanning electron microscopy (SEM) was used to image and characterize the 
surface morphology of the hydrogel samples.  Each sample was fixed overnight at 
room temperature using Karnovsky’s fixative (a mixture of 2.5% Glutaraldehyde, 
2.0% Formaldehyde buffered with 0.1M Cacodylic Acid in ddH20).  The samples 
were washed with three changes of 1X PBS and then washed three times with 
ddH2O.  The sample is again fixed, this time incubating in a 0.1% Osmium Tetroxide 
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in ddH2O fixative for 30 minutes.  The samples are again washed three times using 
ddH2O.  The samples were dehydrated using the succession of ethanol (electron 
microscopy grade) changes, as follows: 
• 50% EtOH  10 minutes 
• 70% EtOH  10 minutes 
• 85% EtOH  10 minutes 
• 95% EtOH  10 minutes 
• 100% EtOH  15 minutes 
• 100% EtOH  15 minutes 
Upon completion of the ethanol dehydration, leave the samples in 100% 
EtOH overnight.  The samples are then infiltrated using a 1:1 mixture of EPON resin 
and 100% EtOH for 4-6 hours in the refrigerator (4°C), then embedded in 100% 
EPON resin and placed in the drying oven (60-70°C) for 24 hours.  The embedded 
samples are then sectioned using the microtome (Figure 28) and a glass the sections 
are captured for imaging using a small copper circle with a carbon mesh grid.  The 
samples are stored overnight in a desiccator to dry and then further fixed for cells 
using 4% Uranylacetate for 30 minutes in the dark, in order to stain the nucleic 
acids, proteins and free amino groups. This is follow by a staining of cellular 
membranes using Reynold’s lead citrate, for one minute in the absence of CO2.  The 
samples were then dried for at least two hours prior to imaging, again in a 
desiccator.  The samples were then imaged using the Hitachi H7600 Transmission 
71 
Electron Microscope (Figure 29) at the Advanced Materials Research Laboratory 
(Clemson University Electron Microscope Facility, Anderson, SC). 
3.4.5 Immunohistochemistry for analysis of vimentin, α-smooth muscle 
actin, and laminin presence 
The immunohistochemistry (IHC) protocol was adapted using the general 
IHC protocol that was developed by a former lab member, Dr. James Chow.  Samples 
were sectioned onto glass slides as described in 3.1.3.1.  The slides were 
deparaffinized in xylene and rehydrated to water using succession of decreasing 
ethanol concentrations.  For antigen retrieval, the sections were circled using the 
wax Vector Immedge Pen and 2N hydrochloric acid (HCl) was dropped onto each 
individual section and incubated for 20 minutes.  The slides were then rinsed using 
a tris buffer saline (TBS) two times for 5 minutes.  The slides were rinsed in 0.025% 
triton for 5 minutes in order to permeabilize the sections and were again rinsed in 
TBS for 5 minutes.  A 1.5% normal blocking serum made from normal horse serum 
Figure 28: Microtome for Sectioning for 
Transmission Electron Microscopy 




in TBS was used to block non-specific binding for 45 minutes.  The normal blocking 
serum was wicked from the slides and the primary antibody in TNB buffer was 
added to the sections, Vimentin(Abcam, ab92547) at a concentration of 4ug/ml, α-
smooth muscle actin (Abcam, ab5694) at a concentration of 5ug/ml, and laminin at 
a concentration of 40ug/ml (Abcam, ab11575) and was incubated at room 
temperature for 1 hours.  Following the primary antibody incubation, the antibodies 
were extracted and saved, rinsed twice with TBS.  The endogenous peroxidase was 
blocked using a 0.3% H2O2 and 0.3% normal horse serum in TBS for 30 minutes, 
rinsed with TBS for 5 minutes, and the secondary biotinylated antibody was applied, 
made of 30μl normal horse serum and 10 μL anti-mouse in 2 mL TBS for 30 minutes 
at room temperature.  The slides were again washed using TBS two times for 5 
minutes and then were incubated in the Avidin Biotin Complex for 30 minutes.  
Again, the slides were rinsed with TBS and then were developed using the DAB 
solution, made of 5mL H2O, 2 drops of Buffer Stock solution and 4 drops of DAB 
solution from the Vector kit, and 2 drops of H2O2.  Once the brown tint of the 
sections was observed the slides were then quenched using ddH2O.  The slides were 
then imaged using a light microscope at the 10X magnification. 
3.4.6 Western blot for α-smooth muscle actin and laminin 
Using a protocol previously established by Dr. Jeremy Mercuri in the BTRL, 
the protein of various samples was extracted using RIPA buffer for 20 minutes on 
ice.  The protein concentration was determined using a Bicinchoninic acid (BCA) 
colorimetric assay.  The samples were prepared so there were 20 μg of protein per 
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well using reducing buffer and ϐ -mercaptoethanol.  SDS-PAGE was run for 90 
minutes at 100V prior to western blotting.  The gels were transferred to PVDF 
membranes and run for 60 minutes at 100 V.  The membranes were then blocked in 
2% Non-fat dried milk (NFDM) for 2 hours and then incubated in the primary 
antibody in 2% NFDM.  Then they were washed in Tris-Tween 3x and in 0.5% NFDM 
2x, then in the secondary primary for 90 minutes.  The membranes were then 
washed in Tris-buffer, prepared in detection solution (Thermo Fischer) and imaged 
using the ChemiDoc MP+ (BioRad). 
3.5 Study 5: Injection of cell-seeded hydrogels into the base of the aortic 
cusp  
3.5.1 Method of injection 
First the isolated aortic root was mounted in an aortic root mount, as shown 
in Figure 30Error! Reference source not found..  Using the injection protocol 
previously established by a student in our lab, Allison Kennamer49, the aortic cusps 
were injected in the following manner.  All materials were sterilized using either the 
autoclave (121°C) or ethylene oxide.  Human adipose stem cells were passaged, as 
described in 3.3.1, and reconcentrated to the desired cell density of 3.2x106 
cells/mL.  One mL of the cell dense hydrogel solution was pre-loaded into three 
separate syringes (one per cusp). Using a 27 GA x11
4
 inch needle connected to an air 
pump, sterile air was pumped into the base of the cusp at about 15-20 psi, which 
inflated the cusp.  Using the same size needle, about 0.5 mL of the pre-loaded 
hydrogel solution was injected into the inflated aortic cusp.  The same injection 
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method was repeated for all three cusps on the same mounted aortic root.  The root 
was then transferred into the assembled valve bioreactor.  
 
Figure 30: Sutured aortic mount 
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3.5.2 Bioreactor assembly and conditioning 
The valve bioreactor was assembled based on the instruction of Dr. Lee 
Sierad, a former student in the BTRL.  Once fully assembled, as shown in Figure 32: 
Assembled bioreactor the bioreactor was filled to the fill line using 700-mL of 
culture media.  A second round of antibiotic/antiomycotic was added to the media 
after 3 days of conditioning.  The valves were pre-conditioned using a ramp up 
scheme as shown in.  The valve was slowly subjected to higher pressures each day, 
reaching pulmonary pressures on day 3 and conditioned there for the next four 
days, for a total of one week (Figure 31). 












Figure 32: Assembled bioreactor 
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3.5.3 Histological Analysis 
The cusps were extracted and placed in 4% Paraformaldehyde overnight, 
and then processed using the Tissue Tek Processor.  They were then embedded, 
sectioned, and stained for H&E and DAPI to determine if cells were viable in the 
bioreactor, as described in 3.1.3.1. 
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CHAPTER 4: RESULTS AND DISCUSSION 
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4.1 Study 1: Fabrication of hydrogel using decellularized aortic cusps 
4.1.1 Decellularization Analysis 
Figure 33 shows the histological tests to determine that there was proper 
decellularization of the aortic cusp.  The H&E and DAPI stains both show that the 
nuclei of the cells have been removed fully through the decellularization process.  
The fresh aortic cusp H&E stain shows purple staining indicating the presence of 
cells in the ECM, while the decellularized stain does not show this.  A DAPI stain, an 
immunofluorescent nuclear stain, shows the nuclei of cells as a bright blue 
fluorescence.  Again, the fresh show that there is the presence of cells, while the 
decellularized cusp shows no presence of cells.  Staining for Movat’s pentachrome 
stains nuclei red, elastin dark purple, GAGs blue, and collagen yellow.  It can be seen 
that there is a presence of GAGs in the fresh cusp, but there is no presence of GAGs 
in the decellularized cusp.  The color of the gross, fresh cusp is shown to have a 
brownish tint, while the decellularized cusp is shown to be a ghost white color.   The 
removal of DNA was examined using gel electrophoresis, as shown in Figure 34, and 
it is seen in lanes 2-5 that DNA is present in fresh aortic cusps, but is absent in lanes 
7-11 corresponding to the decellularized aortic cusps.  This absence indicates the
proper removal of DNA and RNA during the decellularization process.  Overall, the 
histology and gel electrophoresis indicates that the aortic cusps were completely 




Figure 33: Decellularization analysis of porcine aortic cusps 
 
Figure 34: Agarose gel electrophoresis of fresh and decellularized porcine aortic cusps 
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4.1.2 Fabrication of decellularized porcine aortic cusp based hydrogel 
The goal of this pilot study was to successfully isolate and decellularized 
aortic cusp tissue and then use the protocol described in 3.1.5 to solubilize the cusp 
and fabricate a hydrogel structure at physiological conditions.  Figure 35 shows the 
successful fabrication of two different aortic cusp-derived hydrogels (ACG).  The 
comparison between the two fabricated hydrogel reveal two basic, yet key 
properties of the hydrogel.  Once cross-linked, this hydrogel is capable of 
maintaining the structure of container that the hydrogel was formed (or cross-
linked) in.  The hydrogel can be molded into both thick, 3-dimenional structures (A) 
with the potential for a 3-dimensional scaffold and molded to form a desired 
structure such as the shape of an aortic cusp (B).  The hydrogel also shows the 
ability of the hydrogel to maintain its crosslinked structure once removed from 
physiological temperatures (37°C).  This means that the gelation process is not 
spontaneously reversible at room temperature, once the initial bonding has formed. 
Figure 35: Successful fabrication of ECM hydrogel 
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4.2 Study 2: Characterization of aortic cusp-derived hydrogel 
4.2.1 Comparison of different concentrations of hydrogels 
The goal of this study was optimize the concentration of the aortic cusp-
derived hydrogel through visualization of the reformed matrix, comparison of 
characterized properties, as well using knowledge acquired from similar studies in 
literature.  The first step in determining what the best concentration is of 
extracellular matrix in the hydrogel is do histology on the structure that is produced 
via gelation (Figure 36).   The H&E histology stains (36, top) reveals how the 
structures form after gelation, showing that as the concentration present in the cells 
decreases, the structure formed loses the distinct formation of the fibers.  The 
highest concentration of extracellular matrix used was 6 mg of extracellular matrix 
per 1 ml of solution.  This concentration showed distinct collagen fibers formed and 
noticeable pores formed within the matrix, which is important for cell-seeding in 
tissue engineered scaffolds.  The lower concentrations (4.5 and 3 mg/ml) of 
extracellular matrix hydrogels do not show the same distinct fiber formation, nor 
have the same distinct pores.  The lack of fiber formation in lower concentration 
leads to the conclusion that there would be limited interactions with the matrix, as 
there is not a distinct structure to adhere to.  Their lack of distinct pores are most 
likely due to the lack of sufficient concentration of collagen to reform proper 
collagen fibers.  Further analysis of the architecture using Masson’s Trichrome 
confirmed the formation of denser collagen fibers in the higher concentration 
hydrogel.  Another interesting presence was discovered in the staining of the 
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hydrogels, the pink color that is present indicates muscle fibers are reforming in this 
matrix.  This is interesting, and is probably the result of the isolation process of the 
porcine valves.  There is one cusp in the porcine valve that contains a mix of muscle 
and collagen and elastin.  What this shows is that the muscle fibers will also reform 
as a result of this gelation process. 
The collagen content for all three hydrogel concentrations, as well as the 
fresh aortic cusp and decellularized aortic cusp was tested using a hydroxyproline 
assay, Figure 37.  This test was run to see how much of the collagen was retained 
throughout the decellularization process, as well as the formulation of the 
extracellular matrix hydrogel.  It was found that the native cusp has an average 
collagen content of 453 μg/mg and the decellularized cusp had an average of 445 
μg/mg. These values were not found to be statistically significant, therefore the 
decellularization process does not degrade the collagen in any significant manner.  
The varying concentrations of aortic cusp hydrogel were also tested and found to 
have values as follows: 6 mg/ml has a concentration of 255 μg/mg, 4.5 mg/ml has a 
concentration of 317 μg/mg and 3 mg/ml has a concentration of 270 μg/mg.  These 
were not found to be statistically significant across the three concentrations, but 
they were found to be statistically different from the fresh and decellularized cusp. 
This difference can be explained through the process of solubilization of the ECM.  
This process uses pepsin to break down and solubilize the tissue, which works by 
breaking down the triple helix structure of collagen and can then become soluble.  
Upon reformation, some of the collagen may not reform the triple helix structure, 
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resulting in the approximately 40% loss of total collagen content by weight.  This 
also leads to the assumption that some other ECM components are preserved 
throughout the process of fabrication of the hydrogel, due to the dry tissue weight 
remaining is still around 700 μg/mg.   
A summary of various other parameters of the hydrogels is shown in Figure 
38, which summarizes the conditions at which these hydrogels are fabricated, the 
equilibrium water content percentage (%EWC), the swelling ratio, and the solubility 
percentage (%), as well as the collagen content.  These parameters were all tested 
against PureCol®, a hydrogel made of pure collagen already on the market.  The 
EWC of all the hydrogels was found to range from 97.5-99.1% indicating the high 
fluid content of these hydrogel scaffolds.  The swelling ratio, which indicates the 
amount of fluid, relative to their own size, that a hydrogel can take in after the initial 
gelation process occurs.  These values ranged from15-20% with no significant 
difference across all samples, meaning that these hydrogels can take in an extra 
15% of fluid while in the body.  This parameter is important to take in to account, 
because the hydrogel should be swollen prior to injection to avoid uptake of 
undesirable fluids in the hydrogel upon injection into the body.  The collagen 
content was also compared to PureCol®, which as its name suggests, is almost pure 
collagen.  Advanced Biomatrix lists its collagen content as >99% collagen type I.  
While this leads to a reduction in variability in how the hydrogel performs, it means 
that there is no other ECM components present in the hydrogel for proper cell 
signaling and adhesion.  From these studies, it was determined that a concentration 
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of 6 mg/ml for the hydrogels is best for cell encapsulation, due to its similarity in 
microstructure to that of the native ECM. 
Figure 36: Comparison of hydrogel concentrations using histology 
Figure 37: Hydroxyproline assay for collagen content 
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Sample ACG (6mg/ml) ACG (4.5mg/ml) ACG (3mg/ml) Pure Col 
Gelation pH 7.2-7.6 7.2-7.6 7.2-7.6 7.2-7.6 
Gelation Temp(°C) 32 32 32 37 
%EWC 97.5%±0.9 99.1%±0.2 97.9%±1.1 98.7%±0.3 
Solubility (%) 68.3%±6.8 71.6%±21.0 77.4%±3.3 88.0%±14.5 
 




255 ±17.4* 316±70.1* 270±40.8* 933±48.3 
Figure 38: Summary of properties of different hydrogels. (* denotes P<0.05 compared PureCol®) 
4.2.2 Analysis of porosity 
The porosity of a tissue engineered scaffold is a very important characteristic 
to account for in tissue regeneration.  The porosity of this hydrogel was quantified 
using H&E sections and the ImageJ software (Figure 39), then compared to that of 
the decellularized aortic cusp and the PureCol hydrogel.  The pore number, pore 
size, and pore area were all studied for each sample type and compared to for 
statistical significance.  The aortic cusp derived hydrogel was found to have much 
larger pore size (47μm2) when compared to the decellularized cusp and the 
PureCol®.  The pore number of the AC hydrogel was decreased over the same area.  
This increase in pore size seems to be inversely correlated to the pore number, 
which can be explained by the pore size increasing, leading to a decrease in the area 
available for other pores on the image.  The pore size and pore number values were 
both statistically different from the PureCol® and decellularized cusp.   
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This larger pore size is conducive to the effectiveness scaffold for cell 
encapsulation and migration.  Thus, the fabrication of this highly porous scaffold 
with cells already encapsulated in the hydrogel should help with cell migration in 
the scaffold, as compared with the decellularized cusp and PureCol®.  This hydrogel 
also offers the advantage over a traditional tissue construct, as it is easy to 
encapsulate prior to reforming the ECM, thus a uniform distribution of cells should 
theoretically be attained during cell encapsulation. 
Figure 39: Porosity analysis 
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4.2.3 Rheological studies for viscosity of hydrogel 
Three rheological trials were run using different settings for the maximum RPM 
tested, plotting the shear stress vs shear rate and each fit with a power law model 
(Figure 40,A).  The maximum viscosity recorded was found to be 76.80 mPa*s at a 
shear rate of 3.80 s-1 and the minimum viscosity recorded was 30.72 mPa*s at a shear 
rate of 57 s-1 (Figure 40, B).  The decreasing viscosity of the fluid was plotted against the 
shear rate with a power law model trend line (Figure 40, C).  These numbers were then 
compared to the literature value for PureCol®, which was between 23 and 27mPa*s.50
 
Figure 40: Rheological analysis of hydrogel 
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The rheological studies for viscosity of the aortic cusp derived hydrogel 
revealed a key property of the precursor.  The precursor to the hydrogel does not 
behave like a Newtonian fluid, which exhibits a linear relation of shear stress (τ) to 
shear rate (ϒ), and thus a constant viscosity in different environmental conditions.  
Rather, the fluid precursor fit best to the non-Newtonian model known as the power 
law model.  This particular model is indicative of a fluid that exhibits shear-thinning, or a 
pseudo-plastic behavior, which means that it has a decrease in the viscosity as it is 
subjected to larger shear stresses.  This shear thinning property is characteristic of the 
Van der Waals and hydrogen bonds that are holding together the polymers of the 
hydrogel precursor solution, due to the breaking of those weak bonds under higher 
shear stresses.33  This characteristic is very important for injectable hydrogel, as this 
characteristic can determine the applications that the hydrogels are capable of.  For a 
relevant comparison, this hydrogel was compared to PureCol®, a collagen solution 
already on the market with a viscosity of 23-27 mPa*s.  The viscosity of the aortic-cusp 
derived hydrogel was found to be much higher at low shear stresses (76.8 mPa*s).  The 
shear-thinning property of this hydrogel means that this material will not be well suited 
as an injectable hydrogel for drug delivery, due to its viscosity changing throughout the 
injection process.  When the viscosity decreases, this subjects the drug that is imbibed 
to leaking out of the non-crosslinked solution prior to reaching its destination point.  
However, this shear thinning characteristic is what makes this hydrogel material very 
appealing for cell delivery.  The viscosity coupled with the lubrication effect caused by 
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the stress shearing of the hydrogel of the solution should act to shield the encapsulated 
cells upon injection from the shear stresses subject to the hydrogel. This means that the 
hydrogel solution should be much better at shielding the encapsulated hADSCs from the 
shear stress when compared to PureCol®, theoretically resulting in a higher viability 
from injection.  It should be noted that this test was performed at ambient room 
temperature and temperature has been shown to have an inverse effect on the viscosity 
of a polymer solution.51  Ambient room temperature (≈25°C) was used for two reasons:  
one, if this polymer solution is heated to >32°C then the solution will be subjected to 
spontaneous gelation, and two, the injection would most likely be taking place initially 
at room temperature, and therefore is a realistic representation of the application. 
However, this inverse temperature dependency of viscosity means that it may be 
possible to counteract this shear-thinning effect with cooling of the solution prior to 
injection. 
4.3 Study 3: Encapsulation of hADSCs onto different hydrogel scaffolds 
Human adipose-derived stem cells were encapsulated at a density of 400,000 
cells/ml onto each hydrogel and placed inside a 24-well plate, as well as using the 
PureCol® hydrogel as a control and scaffolds with no cells encapsulated as the 
negative control.  The tracking of this contraction of the hydrogels was qualitatively 
visualized over time (Figure 41, A).  The AC hydrogel was found as the only hydrogel 
that exhibited a contraction over a 22 day study.  This contraction was found to have 
a rate most closely resembling an exponential rate, as seen in Figure 41, B.  The cell 
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viability of the scaffold was tested and found to be viable to cells, however it was 
revealed that there was not a high density of cells inside any of the 3-D constructs. 
The contraction of the AC hydrogel with cells encapsulated into them prior to 
plating exhibited a contraction that is indicative if a material remodeling through 
cellular adhesion.  This phenomena was not observed in the PureCol® hydrogel, 
with or without cells.  This suggests one of two possibilities: that the PureCol®, is too 
dense for the cells to detach from the well-plate and therefore never contract.  It 
also may suggest that there are biological cues present in the AC hydrogel that are 
signaling the cells to contract and remodel the hydrogel.  This theory is furthered by 
the collagen content of the hydrogel only making up for about 30% of the dry 
weight, meaning there is probably elastin and other proteins retained from the 
aortic cusp.  The low density of the cells inside the 3-D constructs, shown by a 
LIVE/DEAD assay, led to a further study with varying concentrations of cells, 
discussed in 4.4.  This live/dead assay showed decent viability, but there were not 
enough cells present to draw a conclusion. 
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Figure 41: Contraction comparison of different hydrogels 
Figure 42: Live/Dead of contractile study 
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4.4 Study 4: Hydrogel encapsulation of hADSCs in varying densities 
4.4.1 Contraction of hydrogels with varying cell density 
Based on the previous study, a contractile study of the AC-derived hydrogel 
was used to attempt to characterize the effect of cell density on the rate of the 
contraction (Figure 43, A).  The rate of contraction was compared across all study 
groups over a course of 12 days (Figure 43, B), upon which the highest dense 
hydrogel was fully contracted and the study was stopped for viability testing. The 
rate of contraction for the group seeded with 3.2 million cells/mL was graphed and 
found to have a rate that seems to be trending towards an exponential rate (Figure 
44, A), or otherwise has an initial surge of contraction then settling to a more linear 
rate of contraction (Figure 44, B).  This initial surge can be explained by the 
detachment of the hydrogel from the well plate.  This detachment process requires 
the cells to “pull” against the matrix much more to get the hydrogel to remodel, 
resulting to a higher rate initially once detachment occurs.  This is further evidenced 
by the initial contraction in the lower cell density hydrogels seemingly not 
contracting until around day 4. This is probably how long it takes for the cells to 
accumulate enough force to break the adhesion to the well plate and begin 
remodeling the hydrogel. 
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Figure 43: Contraction comparison of cell-encapsulated hydrogels 
Figure 44: Contraction rate for cell-encapsulated hydrogels 
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4.4.2 Live/Dead cytotoxicity assay 
The cytoxicity of each hydrogel was concentration was assessed using a 
live/dead assay (Figure 45).  This assay showed there was an extremely high 
number of cells that were retained on the scaffold, relative to the number of dead 
cells.  The viability was quantified using the live/dead images and ImageJ (NIH 
freeware) to analyze the cell count of each.  The viability of the AC hydrogel was 
found to range between 91-95% at day 12 (Figure 46) 
The live dead images in Figure 45 reveal the high viability of the hydrogel for 
cell encapsulation under static seeding conditions.  The Live/Dead images also 
revealed an interesting tendency of the cells, which was to adhere to the edges of 
the scaffold and pull the scaffold inward.  This suggests that the hADSCs 
encapsulated migrated to the edges of the scaffold and began the remodeling 
process, which resulted in a shrunken tissue like structure.  The images in at 10x 
show a better view of this adherence, as the cells look as though they have stretched 
out along the edges of this valve to grab the collagen fibers.  The quantified viability 
of 95% in the high-density seeded hydrogels, shows the extreme viability of this 
hydrogel, when compared to other similar scaffolds (Figure 46) shown to have 
success in hADSC encapsulation.  This is probably do to the structural components 
more closely resembling the native ECM, thereby keeping the cell more likely to not 
initiate apoptosis.  The higher density of cells also trended to a higher viability when 
compared to the low density of cells (95% vs 91% viability), which suggests that the 
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presence of other cells help viability and thereby suggests the initiation normal 
cellular processes indicative of proper cellular function. 
Figure 45: Live/Dead assay for cell encapsulation study 
Figure 46: Viability analysis and comparison of various hydrogels52 
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4.4.3 Biochemical analysis of cell-encapsulated hydrogels 
The Glycosaminoglycan (GaGs) content was analyzed via a DMMB assay to 
determine if there was a restoration of GaGs in the cell-encapsulated hydrogels.  It 
was found that there was a modest return of GaGs in the hydrogel, but it was not 
found to be statistically significant (Figure 47).  Each group was also stained for α-
smooth muscle actin (α-SMA), laminin, and vimentin using immunohistochemistry, 
all proteins found in the extracellular matrix important to the cell mobility and 
function (Figure 48).  It should be noted that an alternative antigen retrieval 
process, due to the recommended one removing the hydrogel section from the slide, 
and it was very difficult to obtain a clear image as a result, and therefore are not 
reliable.  IHC revealed the positive stain for Vimentin across all sample, a positive 
stain for α-SMA in Group B, and possibly group A.  Laminin did not seem to be 
positive in any of the samples.   
The presence of GaGs in cell-encapsulated hydrogels and not in 
decellularized cusps or non-encapsulated hydrogels, suggest that the cells are 
secreting GaGs while interacting with the scaffold.  This is important to note, 
because the presence of GaGs is extremely integral in the tri-layered structure of the 
native aortic valve, and is important in the proper lubrication of the valve.  As this 
study was a short term, two week study, these GaGs content would be expected to 
rise over time, as the cells continue to secrete the GaGs.   
A positive stain for α-SMA is characteristic of activated VICs, and a positive 
stain for Vimentin is characteristic of the fibroblast phenotype.  The positive stain 
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on the scaffold would indicate that the presence of cells on the hydrogel results in 
the differentiation into activated VICs for α-SMA and into fibroblasts for vimentin.  
The protein analysis of the hydrogels seeded with ADSCs shows that there was a 
positive stain for α-SMA, which is indicative of activated VICs (Figure 49).  The non-
descript protein commassiee stain shows more protein than just collagen type I is 
present for cell-signaling.  This is extremely important for the proper cell 
differentiation signaling in stem cells.  
Figure 47: GAGs analysis of tissue samples 
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Figure 48: Immunohistochemistry for Vimentin, Laminin, and α-Smooth Muscle Actin 
Figure 49: Protein Analysis of aortic cusp derived hydrogel 
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4.4.4 Electron microscopy for analysis of microstructure 
The morphology of the cell-encapsulated was investigated using electron 
morphology to determine the cell interactions with the extracellular matrix.  SEM 
was used to see the surface interactions of the cell with the collagen networks in 
hydrogel (Figure 50).  Adhesion interaction of the cells to the matrix was visualized, 
with a specificity to the collagen, no cells were visualized binding to the elastin 
presence.  Globular structures were visualized on the surface of the cells.  Elastin 
was visualized inside the matrix morphology, further indicating the retention of 
extracellular matrix components.  The collagen diameter was analyzed using ImageJ 
to confirm the reformation of the fibers is functional (Figure 51).  The collagen 
diameter formation was found to be within a range of 64-73μm, indicative of a 
functional type I collagen fiber.  Transmission electron microscopy was used to 
visualize inside the cellular membrane (Figure 52), showing the intact cellular 
components confirming the viability of these hydrogels. 
The globular structures seen in Figure 50, (B and C) shows that the cell is 
secreting proteins, indicating the proper functionality of these cells.  These globular 
structures may be the GaGs, which we found to be present in the DMMB assay, or 
they could be adhesion proteins aiding in their adhesion to the extracellular matrix.  
The functioning secretion of these proteins is evidence of an intact Golgi apparatus 
and other cellular components important in the creation and secretion of proteins.  
Further evidence of this is seen in Figure 52, with the presence of intact cellular 
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components.  The functional collagen diameter reformation is extremely important 
to this scaffold (Figure 51), as this shows that the process of fabrication with the 
pepsin breakdown does not degrade the collagen irreversibly.  This leads to the 
functional reformation of the collagen, and therefore a functional binding by the 
hADSCs.  
Figure 50: Surface morphology of cell encapsulated hydrogel 
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Figure 51: Collagen fiber diameter analysis53 
Figure 52: Transmission electron microscopy. 
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4.5 Study 5: Injection of cell-seeded hydrogels into the base of the aortic 
cusp 
The injection of the encapsulated hydrogel into the base of the cusp was 
investigated to determine if this scaffold would improve upon the viability that was 
previously investigated by Allison Kennamer49, a former student in the BTRL. The 
initial visualization of the opening and closing of the valve in the bioreactor showed 
the valve to be functioning normally, meaning the injection method did not affect 
functionality of the valve.  Unfortunately, there was contamination after day 5 of the 
study, when a leak occurred in the tubing.  Figure 53 shows the H&E of the injected 
cusps, which shows there are no cells present at the end of day 7, DAPI confirms 
this. 
This study shows how difficult it is to see cells effectively on to the aortic 
cusp, as the cusp is subject to mechanical forces that wash the cells away.  The 
hydrogel precursor was meant to protect the encapsulated cell, but the reverse 
seems to have been the case. The cells probably adhered to the hydrogel precursor, 
which did not bind to the spongiosa layer of the aortic cusp upon gelation and was 
washed away with the mechanical forces.   
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Figure 53: H&E and DAPI of injection study 
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CHAPTER 5: CONCLUSIONS 
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In cardiovascular tissue engineering, a more clinically relevant valve 
replacement needs to be achieved through the full recellularization of the heart 
valve scaffold.  In the presented work, a new hydrogel material was developed, 
optimized, and characterized to reproducibly encapsulate of stem cells inside the 
scaffold.  Through the analysis of the microstructure and biochemical properties of 
this hydrogel, it was found that this new hydrogel scaffold has a highly viable 
structure for the encapsulation of hADSCs.  To support this conclusion, we 
compared the viability to hydrogels already on the market in similar conditions, and 
it was found to have a significantly higher viability in static conditions. 
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6.1 Determining diffusion of cells from hydrogel 
Encapsulating cells inside the hydrogel allows the cells to bind to the scaffold 
and begin remodeling the hydrogel into a more tissue like structure.  Due to this fact 
there is the concern that the cells are content with being contained inside the 
hydrogel and won’t remodel the ECM of the surrounding damaged tissue.  A simple 
rate of diffusion from hydrogel to a surrounding scaffold and viability test would be 
sufficient to determine the effectiveness of this material as a potential material for 
the delivery of cells to diseased tissue. 
6.2 Viability of cells encapsulated in hydrogels: static vs. injection 
It was found that this hydrogel is what is known as a shear-thinning material.  
Due to this property’s presence, the cell-encapsulation capabilities of the hydrogel 
may be compromised, due to the viscosity being lessened in greater shear stress.  
The shear stress that is brought on by the injection through a needle may lead to the 
cells on the outer parts of the hydrogel precursor diffusing out much more readily 
than those hydrogels that are not subject to high shear stress prior to formation.  
Also, the cells encapsulated may not be as well protected after injection compared to 
prior to injection, resulting in a decrease in cell viability on the scaffold.  The 
hydrogel should be tested using different gauge needles to determine the optimal 
needle size for retention of viability.  The hydrogel should be compared to cells in 
cell culture media, as well as collagen gels already on the market.  When using a 
material for cell delivery, the FDA requires at least 70% viability upon completion, 
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so it must be determined whether this hydrogel meets these requirements post-
injection. 
6.3 Long term dynamic conditioning studies in the bioreactor 
The initial pilot bioreactor study was only performed for a short, one week 
period and only in one aortic root complex (3 cusps).  Future studies should include 
the preconditioning of injected valves with this cell-encapsulated hydrogel to see if 
the cells differentiate into VICs under the mechanical cues of a bioreactor, while 
encapsulated in the hydrogel over the course of a month long study. This should be 
compared to the results of static controls, as well as to previous valve bioreactor 
injection studies without the presence of the hydrogel.   
The effect on the mechanics of the valve should be tested.  There is a 
possibility that the presence of a hydrogel could act as a reinforcement to the valve, 
allowing it to further withstand the stressful environment of the cardiovascular 
system.  Using the Bose, or other means of fatigue testing, the valves mechanics 
should be compared to that of the native valve, as well as the decellularized valve 
without the hydrogel injection. 
6.4 Large animal studies to determine site-specific compatibility 
We have shown that this hydrogel is extremely viable for the encapsulation 
of cells.  In order to determine if this hydrogel can translate into in vivo environment 
safely, the hydrogel should be tested in a large animal model, such as a sheep or pig, 
in order to see if the hydrogel would induce an immune response, as well as to test 
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to see if the stem cells would differentiate into the desired q-VIC phenotype while 
inside an animal model. 
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APPENDIX 
Appendix A: Applications of hydrogels28 
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